

CITATION REPORT

List of articles citing

**In vivo gene delivery and stable transduction of
nondividing cells by a lentiviral vector**

DOI: 10.1126/science.272.5259.263
Science, 1996, 272, 263-7.

Source: <https://exaly.com/paper-pdf/26752774/citation-report.pdf>

Version: 2024-04-04

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2224	Prospects for Gene Therapy of Sickle Cell Disease and Thalassemia. 791-814		
2223	Strategies for gene transfer to solid organs: viral vectors. <i>Methods in Molecular Biology</i> , 2006 , 333, 175-200	3	
2222	A self-initiating eukaryotic transient gene expression system based on contransfection of bacteriophage T7 RNA polymerase and DNA vectors containing a T7 autogene. 1994 , 22, 2114-20		26
2221	Retrovirus infection of cells in vitro and in vivo. 2001 , Chapter 9, Unit9.14		8
2220	Overview of the retrovirus transduction system. 2001 , Chapter 9, Unit9.9		13
2219	Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. 1996 , 7, 2203-8		12
2218	Les vřicules de l'ADN. 1996 , 1996, 20-26		0
2217	Systeme nerveux central: des cellules au pluriel. 1996 , 1996, 35-38		
2216	Quand le muscle s'exprime. 1996 , 1996, 42-44		2
2215	Immune responses to adenovirus vectors in the nervous system. 1996 , 19, 497-501		144
2214	A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. 1996 , 7, 1947-54		467
2213	Viral vectors for modulating gene expression in neurons. 1996 , 6, 576-83		69
2212	Neuronal progenitors as tools for cell replacement in the nervous system. 1996 , 6, 688-95		127
2211	Transcriptional Silencing of Retroviral Vectors. 1996 , 3, 365-378		
2210	Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. 1996 , 93, 15266-71		324
2209	Mechanisms of cytokine-mediated localized immunoprotection. 1996 , 184, 1597-600		27
2208	Fusigenic viral liposome for gene therapy in cardiovascular diseases. 1996 , 93, 11421-5		156

2207	Neuronal damage and its relation to dementia in acquired immunodeficiency syndrome (AIDS). 1996 , 64, 295-307	9
2206	Symposium session summaries. 1996 , 22, 78-208	
2205	Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. 1996 , 93, 11382-8	1258
2204	Cell-surface receptors for retroviruses and implications for gene transfer. 1996 , 93, 11407-13	119
2203	Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. 1996 , 93, 14070-5	59
2202	Ex Vivo and In Vivo Gene Delivery to the Brain. 1996 , 11, 13.3.1	
2201	Development of HIV vectors for anti-HIV gene therapy. 1996 , 93, 11395-9	118
2200	Suppression of TNF-alpha-induced apoptosis by NF-kappaB. <i>Science</i> , 1996 , 274, 787-9	33.3 2401
2199	Transcriptional Silencing of Retroviral Vectors. 1996 , 3, 365-378	37
2198	Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. 1996 , 222, 415-22	50
2197	The maturation of human gene therapy. 1996 , 85, 1261-5	12
2196	HIV-1, Vpr and the cell cycle. 1996 , 6, 1096-103	158
2195	Human somatic cell gene therapy. 1996 , 18, 999-1007	35
2194	From curse to cure: HIV for gene therapy?. 1996 , 14, 943	8
2193	Two-step gene transfer using an adenoviral vector carrying the CD4 gene and human immunodeficiency viral vectors. 1996 , 7, 2281-6	19
2192	Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. 1996 , 7, 2113-21	38
2191	Gene Therapy Protocols. 1996 ,	1
2190	Flies, genes, and memory engineering. 1996 , 191, 139-43	2

2189	Methods for the construction of retroviral vectors and the generation of high-titer producers. 1997 , 7, 59-78	13
2188	Applications of gene therapy to the CNS. 1996 , 5 Spec No, 1397-404	82
2187	Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. 1997 , 8, 2031-41	30
2186	Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. 1997 , 8, 1891-900	200
2185	Gene therapy for haemophilia. 1997 , 6, 1685-90	4
2184	GaLV pseudotyped vectors and cationic lipids transduce human CD34+ cells. 1997 , 8, 1685-94	12
2183	Two-step delivery of retroviruses to postmitotic, terminally differentiated cells. 1997 , 8, 57-63	7
2182	Gene therapy for inherited retinal degeneration. 1997 , 81, 795-801	19
2181	Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. 1997 , 8, 659-69	150
2180	Lentiviral vectors for gene therapy of cystic fibrosis. 1997 , 8, 2261-8	102
2179	Corneal ulceration in the developing world--a silent epidemic. 1997 , 81, 622-3	154
2178	Gene therapy for the eye. 1997 , 81, 620-3	8
2177	Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. 1997 , 8, 1459-67	35
2176	Scientific and political impediments to successful islet transplantation. 1997 , 46, 1247-56	121
2175	HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. 1997 , 94, 9825-30	431
2174	Human Hematopoietic Cell Culture, Transduction, and Analyses. 1997 , 14, 13.7.1	
2173	Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. 1997 , 94, 10319-23	434
2172	Molecular Modification of Neural Networks: Altering Synaptic Function Through the use of Viral Mediated Gene Transfer. 1997 , 113-135	

2171	Lineage analysis using retroviral vectors. 1998 , 36, 51-74		31
2170	Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. 1997 , 8, 423-30		169
2169	Glucose-stimulated genes and prospects of gene therapy for type I diabetes. 1997 , 18, 520-40		38
2168	Gene transfer into human haematopoietic stem cells. 1997 , 18, 291-311		3
2167	Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. <i>Science</i> , 1997 , 278, 1462-4	33-3	59
2166	Genetic therapy. Past, present, and future. 1997 , 44, 153-78		13
2165	Application of ex vivo gene therapy in the treatment of Parkinson's disease. <i>Experimental Neurology</i> , 1997 , 144, 82-91	5-7	34
2164	Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. <i>Experimental Neurology</i> , 1997 , 144, 147-56	5-7	44
2163	Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene. 1997 , 69, 193-8		12
2162	The use of nonneuronal cells for gene delivery. 1997 , 4, 69-102		50
2161	HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. 1997 , 8, 359-70		131
2160	Cell vehicles for gene transfer to the brain. 1997 , 7, 343-51		6
2159	Insights into secretory and endocytic membrane traffic using green fluorescent protein chimeras. 1997 , 7, 631-9		50
2158	Viral vectors for gene therapy of hematopoietic cells. 1997 , 3, 3-19		25
2157	In Response to Freed et al. <i>Cell</i> , 1997 , 88, 173-174	56.2	14
2156	Novel gene delivery to liver cells using engineered virosomes. 1997 , 404, 164-8		30
2155	Integration of visna virus DNA occurs and may be necessary for productive infection. 1997 , 237, 189-97		9
2154	Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. 1997 , 8, 1049-63		56

2153	Use of cloned genetically modified human fibroblasts to assess long-term survival in vivo. 1997 , 8, 523-32	9
2152	Gene therapy: basic concepts and applications in gastrointestinal diseases. 1997 , 58, 87-97	1
2151	Methods and applications of three-color confocal imaging. 1997 , 22, 120-2, 124-6	18
2150	Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. 1997 , 79 Suppl 1, 97-103	22
2149	Versatile Retrovirus Vector Systems for Regulated Gene Expression In Vitro and In Vivo. 1997 , 3, 466-476	52
2148	Gene therapy of haematopoietic cells. 1997 , 242, 95-99	7
2147	Gene transfer trials in clinical haematology. 1997 , 242, 101-107	
2146	HIV-1 nuclear import: in search of a leader. 1997 , 2, d578-87	22
2145	Cellular commitment and differentiation in the cochlea: potential advances using gene transfer. 1997 , 2, 50-60	7
2144	Functional Heterogeneity of Human CD34+ Cells Isolated in Subcompartments of the G0 /G1 Phase of the Cell Cycle. 1997 , 90, 4384-4393	178
2143	Enhanced Host Defense After Gene Transfer in the Murine p47phox-Deficient Model of Chronic Granulomatous Disease. 1997 , 89, 2268-2275	120
2142	Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. 1997 , 94, 14083-8	303
2141	Review: alpha 1-antitrypsin deficiency associated liver disease. 1997 , 12, 404-16	35
2140	Gene therapy for nervous system disease. 1997 , 835, 1-11	14
2139	Gene therapy: regulatory issues and international approaches to regulation. 1997 , 8, 361-9	12
2138	Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+ CD38-hematopoietic progenitor cells. 1997 , 4, 918-27	20
2137	A marriage of viral vectors. 1997 , 15, 840-1	6
2136	Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. 1997 , 15, 871-5	1615

2135	Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. 1997 , 17, 314-7	555
2134	Gene therapy -- promises, problems and prospects. 1997 , 389, 239-42	1477
2133	Gene transfer into haemopoietic cells. 1997 , 10, 445-65	3
2132	Towards efficient cell targeting by recombinant retroviruses. 1997 , 3, 396-403	9
2131	Gene therapy for tissue repair: approaches and prospects. 1997 , 50, 491-500	33
2130	Preface. 1997 , 27, 1-4	7
2129	Delivery of tumor suppressor genes to reverse the malignant phenotype. 1997 , 26, 119-133	4
2128	Gene directed enzyme prodrug therapy for cancer. 1997 , 26, 173-184	24
2127	In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. 1997 , 14, 742-9	84
2126	Biosynthetic retrovectoring systems for gene therapy. 1997 , 75, 249-58	10
2125	Retroviral stem cell gene therapy. 1997 , 15, 162-79	41
2124	Gene transfer into hematopoietic cells. 1997 , 15 Suppl 1, 123-34	12
2123	Gene therapy for diabetes: strategies for beta-cell modification and replacement. 1997 , 13, 209-46	19
2122	Reverse Genetics Meets the Nonsegmented Negative-Strand RNA Viruses. 1997 , 7, 49-63	22
2121	Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. 1998 , 241, 224-33	70
2120	Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. 1998 , 249, 167-74	47
2119	Inhibition of cellular glycoprotein incorporation into human immunodeficiency virus-like particles by coexpression of additional cellular interaction partner. 1998 , 251, 16-21	22
2118	Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. 1998 , 5, 253-63	37

2117	Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. 1998 , 5, 635-44	29
2116	In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. 1998 , 5, 820-7	157
2115	Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. 1998 , 5, 1031-7	65
2114	Gene transfer vectors derived from equine infectious anemia virus. 1998 , 5, 1481-7	193
2113	Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. 1998 , 4, 354-7	390
2112	Lentiviruses as gene transfer agents for delivery to non-dividing cells. 1998 , 9, 457-63	244
2111	Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. 1998 , 31, 153-170	18
2110	Viral Vectors for Gene Therapy. 1998 , 80, 35-47	379
2109	A new non-viral DNA delivery vector: the terplex system. 1998 , 53, 175-82	82
2108	Strategies for achieving multiple layers of selectivity in gene therapy. 1998 , 4, 84-92	28
2107	Prospects for gene therapy for cystic fibrosis. 1998 , 4, 292-9	16
2106	Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis. 1998 , 11, 257-75	6
2105	Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat. <i>Journal of Medical Virology</i> , 1998 , 54, 118-28	19.7 15
2104	Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. 1998 , 143, 681-95	42
2103	Retrovirus-mediated gene transfer into human hematopoietic stem cells. 1998 , 76, 184-92	25
2102	Transduction of non-dividing adult human pancreatic beta cells by an integrating lentiviral vector. 1998 , 41, 736-9	53
2101	Cell targeting by murine retroviral vectors. 1998 , 28, 7-30	20
2100	Recent developments in gene therapy for oncology and hematology. 1998 , 28, 139-51	7

2099	Gene therapy for hemophilia: hopes and hurdles. 1998 , 28, 153-71	13
2098	Expression vectors and delivery systems. 1998 , 9, 447-50	48
2097	Gene therapy for rheumatoid arthritis. 1998 , 20, 197-209	18
2096	Gene therapy of primary immunodeficiencies. 1998 , 19, 493-508	2
2095	Strategies of gene transfer to the kidney. 1998 , 53, 264-72	37
2094	Haemophilia A gene therapy. 1998 , 4, 380-8	11
2093	Thérapie génique antivirale. 1998 , 1998, 69-75	
2092	Viral vectors, tools for gene transfer in the nervous system. 1998 , 55, 399-432	136
2091	Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. 1998 , 56, 119-48	121
2090	Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat. 1998 , 47, 133-40	27
2089	Antidepressant treatments in the 21st century. 1998 , 44, 526-33	98
2088	Methods of gene delivery. 1998 , 12, 483-501	61
2087	Genetic modification of the hematolymphoid compartment for therapeutic purposes. 1998 , 12, 503-18	7
2086	Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells. 1998 , 9, 467-75	44
2085	Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. 1998 , 9, 295-304	59
2084	Vector development: a major obstacle in human gene therapy. 1998 , 30, 413-5	16
2083	Materials and methods relating to the transfer of nucleic acid into quiescent cells. 1998 , 8, 195-201	
2082	Novel lentiviral vectors for human gene therapy. 1998 , 7, 997-1001	

2081	Gene therapy for lysosomal storage diseases. 1998 , 7, 1673-82		5
2080	In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase. <i>Experimental Neurology</i> , 1998 , 151, 249-64	5.7	46
2079	Replication-deficient adenovirus vector transfer of gfp reporter gene into supraoptic nucleus and subfornical organ neurons. <i>Experimental Neurology</i> , 1998 , 154, 353-65	5.7	22
2078	Lineage analysis using retroviral vectors. 1998 , 14, 393-406		43
2077	Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector. 1998 , 149, 419-31		15
2076	Gene therapy for lung cancer. 1998 , 12, 569-94		20
2075	Gene therapy for rheumatoid arthritis. Theoretical considerations. 1998 , 12, 29-41		14
2074	Gene therapy in sports medicine. 1998 , 25, 73-7		10
2073	Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. <i>Science</i> , 1998 , 281, 266-93.3	33.3	149
2072	Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication. 1998 , 26, 3270-8		12
2071	Effects on brain tumor cell proliferation by an adenovirus vector that bears the interleukin-4 gene. 1998 , 4, 237-41		14
2070	Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. 1998 , 9, 2493-502		50
2069	Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells. 1998 , 9, 1025-36		32
2068	Replication-defective HIV as a vaccine candidate. 1998 , 14, 1247-52		8
2067	Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulinitis. 1998 , 9, 2717-26		103
2066	Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. 1998 , 14, 339-45		16
2065	Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. 1998 , 95, 11377-82		231
2064	Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. 1998 , 187, 1439-49		87

2063	Prospects for gene therapy in pediatric neurosurgery. 1998 , 28, 3-14	10
2062	Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector. 1998 , 83, 738-42	40
2061	HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. 1998 , 95, 11939-44	271
2060	Lipofectamine and Related Cationic Lipids Strongly Improve Adenoviral Infection Efficiency of Primitive Human Hematopoietic Cells. 1998 , 9, 2493-2502	45
2059	Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). 1998 , 1, 257-64	18
2058	The Scope of Viral Vectors for the Transduction of Haemopoietic Cells. 1998 , 3, 37-53	
2057	Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. 1998 , 95, 2603-8	86
2056	Chapter 23 Retroviral vectors. 1998 , 381-391	
2055	Vectors for cancer gene therapy. 1998 , 41-77	2
2054	Gene therapy for HIV infection. 1998 , 8, 983-990	2
2053	Interactions between the Immune System and Gene Therapy Vectors: Bidirectional Regulation of Response and Expression. 1998 , 69, 353-409	45
2052	Molecular remedy of complex I defects: rotenone-insensitive internal NADH-quinone oxidoreductase of <i>Saccharomyces cerevisiae</i> mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells. 1998 , 95, 9167-71	139
2051	Genetically Modified Tumor Cell Vaccines. 1998 , 7, 471-485	12
2050	Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. 1998 , 18, 4271-84	204
2049	Cancer gene therapy: connecting basic research with clinical inquiry. 1998 , 16, 2548-56	55
2048	Enhanced gene transfer with fusogenic liposomes containing vesicular stomatitis virus G glycoprotein. 1998 , 72, 6159-63	47
2047	Engraftment and Retroviral Marking of CD34+ and CD34+CD38 ⁻ Human Hematopoietic Progenitors Assessed in Immune-Deficient Mice. 1998 , 91, 1243-1255	82
2046	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. 1998 , 92, 3537-3545	32

2045	A third-generation lentivirus vector with a conditional packaging system. 1998 , 72, 8463-71	2530
2044	Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F. 1998 , 72, 5296-302	21
2043	Development of a self-inactivating lentivirus vector. 1998 , 72, 8150-7	973
2042	Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. 1998 , 72, 9873-80	1481
2041	Characterization of adenoviral gene expression in spinal cord after remote vector delivery. 1999 , 45, 131-7; discussion 137-8	38
2040	HIV-1 nuclear import in search of a leader. 1999 , 4, d772-781	3
2039	Gene transfer in the kidney. 1999 , 276, F1-9	8
2038	Genetic Engineering for Parkinson's Disease. 1999 , 437-XII	1
2037	Gene Deliver Technology. 1999 , 293-322	1
2036	Stem cell directed gene therapy. 1999 , 4, e26-33	17
2035	Lentiviral vectors and gene therapy. 1999 , 4, D481-96	45
2034	Stem cell directed gene therapy. 1999 , 4, e26-33	2
2033	Augmentation of methotrexate resistance with coexpression of metabolically related genes. 1999 , 36, 95-106	1
2032	Advances in Engineering HSV Vectors for Gene Transfer to the Nervous System. 127-163	1
2031	A packaging cell line for lentivirus vectors. 1999 , 73, 576-84	235
2030	Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. 1999 , 73, 2886-92	852
2029	Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. 1999 , 73, 3023-31	90
2028	Species-specific, postentry barriers to primate immunodeficiency virus infection. 1999 , 73, 10020-8	219

2027	Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. 1999 , 73, 728-37	86
2026	Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. 1999 , 73, 1828-34	121
2025	Transfer of the MDR-1 gene into hematopoietic cells. 1999 , 36, 50-64	
2024	Optimizing conditions for gene transfer into human hematopoietic cells. 1999 , 36, 20-49	3
2023	A Clinical Trial of Retroviral-Mediated Transfer of arev-Responsive Element Decoy Gene Into CD34+Cells From the Bone Marrow of Human Immunodeficiency Virus-1Infected Children. 1999 , 94, 368-371	234
2022	Cationic liposome-mediated DNA transfection in organotypic explant cultures of the ventral mesencephalon. 1999 , 6, 190-7	20
2021	Gene therapy for Parkinson's disease: review and update. 1999 , 8, 1551-1564	1
2020	Retroviral vectors for liver-directed gene therapy. 1999 , 19, 27-37	25
2019	Embolization of portal vein branches induces hepatocyte replication in swine: a potential step in hepatic gene therapy. 1999 , 210, 467-77	58
2018	Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. 1999 , 189, 1735-46	360
2017	Viral gene delivery. 1999 , 8, 2159-2172	10
2016	Adeno-associated virus based gene therapy in skeletal muscle. <i>Methods in Molecular Biology</i> , 2000 , 133, 127-56	1.4 4
2015	Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. 1999 , 96, 7041-6	161
2014	Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. 1999 , 96, 12039-43	121
2013	Blood Cell Biochemistry. 1999 ,	1
2012	Vascular gene transfer : from bench to bedside. 1999 , 19, 196-207	41
2011	Thinking globally, acting locally. The promise of cardiovascular gene therapy. 1999 , 84, 1471-2	7
2010	Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease. 1999 , 10, 2539-49	160

2009	Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. 1999 , 96, 3906-10	195
2008	Redox-mediated gene therapies for environmental injury: approaches and concepts. 1999 , 1, 5-27	61
2007	Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. 1999 , 10, 1269-79	23
2006	Efficient transduction of human lymphocytes and CD34+ cells via human immunodeficiency virus-based gene transfer vectors. 1999 , 10, 935-45	60
2005	Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. 1999 , 10, 2221-36	56
2004	Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. 1999 , 10, 1479-89	79
2003	Diverse stabilities of expression in the rat brain from different cellular promoters in a helper virus-free herpes simplex virus type 1 vector system. 1999 , 10, 1763-71	41
2002	Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. 1999 , 10, 1867-73	101
2001	Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. 1999 , 96, 9654-9	55
2000	Metabolic engineering with recombinant adenoviruses. 1999 , 19, 511-44	38
1999	Nucleic acid biotechnology. 1999 , 1, 265-97	39
1998	Gene Targeting Protocols. 1999 ,	0
1997	Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. 1999 , 96, 2988-93	364
1996	Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. 1999 , 96, 10379-84	157
1995	Gene transfer technology in therapy: current applications and future goals. 1999 , 17, 191-202	72
1994	Immunodeficient mice as models of human hematopoietic stem cell engraftment. 1999 , 11, 532-7	30
1993	Recent progress in gene transfer into hematopoietic stem cells. 1999 , 30, 143-58	7
1992	Lentiviruses as gene delivery vectors. 1999 , 10, 448-53	35

1991	Gene therapy of genetic diseases and cancer. 1999 , 3 Suppl 1, 116-21		10
1990	Competitive repopulation of retrovirally transduced haemopoietic stem cells. 1999 , 107, 162-8		25
1989	Large-scale processing of recombinant retroviruses for gene therapy. <i>Biotechnology Progress</i> , 1999 , 15, 1-11	2.8	81
1988	HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. 1999 , 5, 997-103		310
1987	Clinical islet transplantation: a review. 1999 , 875, 189-99		23
1986	Integration complexes derived from HIV vectors for rapid assays in vitro. 1999 , 17, 578-82		45
1985	Beta-galactosidase marker genes to tag and track human hematopoietic cells. 1999 , 6, 3-13		9
1984	Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase--ganciclovir treatment. 1999 , 6, 34-41		29
1983	Cationic lipid-mediated transfection of cells in culture requires mitotic activity. 1999 , 6, 403-11		214
1982	Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. 1999 , 6, 715-28		201
1981	Lentivirus-mediated Bcl-2 expression in betaTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. 1999 , 6, 1160-9		83
1980	Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications. 1999 , 6, 994-1005		56
1979	Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. 1999 , 6, 1258-66		1455
1978	In vivo transduction of mouse epidermis with recombinant retroviral vectors: implications for cutaneous gene therapy. 1999 , 6, 1267-75		76
1977	Adenoviral vectors for in vivo gene delivery to oligodendrocytes: transgene expression and cytopathic consequences. 1999 , 6, 1360-7		25
1976	Stable gene transfer to the nervous system using a non-primate lentiviral vector. 1999 , 6, 1808-18		264
1975	Molecular control of cell cycle progression in primary human hematopoietic stem cells: methods to increase levels of retroviral-mediated transduction. 1999 , 13, 1473-80		23
1974	Development of a flexible and specific gene delivery system for production of murine tumor models. 1999 , 18, 5253-60		145

1973	Self-inactivating lentiviral vectors with U3 and U5 modifications. 1999 , 261, 120-32	153
1972	HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro. 1999 , 263, 55-69	19
1971	Assessing viral gene therapy in neuroendocrine models. 1999 , 20, 296-316	14
1970	Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. 1999 , 253, 170-80	46
1969	Antisense RNA gene therapy for studying and modulating biological processes. 1999 , 55, 334-58	85
1968	[Hematology and internal medicine oncology]. 1999 , 40, 356-68	
1967	Cell engineering for muscle gene therapy: Extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes. 1999 , 30, 173-80	7
1966	Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. <i>EMBO Journal</i> , 1999 , 18, 6771-85	139
1965	Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. 1999 , 93, 172-81	143
1964	Ultrasonographically guided direct gene transfer in utero: successful induction of beta-galactosidase in a rabbit model. 1999 , 181, 848-52	13
1963	Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals. 1999 , 27, 147-54	8
1962	Umbilical cord blood from preterm human fetuses is rich in committed and primitive hematopoietic progenitors with high proliferative and self-renewal capacity. 1999 , 27, 1338-45	86
1961	Retroviral vector-mediated gene transfer into umbilical cord blood CD34 ⁺ CD38 ⁻ CD33 ⁻ cells. 1999 , 27, 1244-54	9
1960	Gene therapy using HVJ-liposomes: the best of both worlds?. 1999 , 5, 298-303	88
1959	Genetic strategies to inhibit HIV. 1999 , 5, 454-8	16
1958	Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. 1999 , 9, 622-31	270
1957	Gene therapy for rheumatic diseases. 1999 , 42, 1-16	145
1956	Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. 1999 , 25, 165-178	25

1955	Up-regulation of amphotrophic retroviral receptor expression in human peripheral blood CD34+ cells. 1999 , 61, 243-53		4
1954	Prospects for the treatment of phenylketonuria by gene therapy. 1999 , 5, 136-143		2
1953	Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. 1999 , 1, 31-42		38
1952	A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells. 1999 , 1, 236-44		26
1951	Lentivirus replication and regulation. 1999 , 33, 133-70		95
1950	Developmental Biology Protocols. 1999 ,		
1949	Transfert génique à visée thérapeutique dans les cellules souches hématopoïétiques et les cellules du système immunitaire. 1999 , 10, 351-356		
1948	Neurotrophic Factors. 1999 ,		2
1947	Vaccines. 1999 ,		
1946	Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. <i>Science</i> , 1999 , 283, 682-6	33.3	598
1945	A role for DNA-PK in retroviral DNA integration. <i>Science</i> , 1999 , 284, 644-7	33.3	223
1944	Lentiviral vectors--the promise of gene therapy within reach?. <i>Science</i> , 1999 , 285, 674-6	33.3	145
1943	Generation of retroviral vector for clinical studies using transient transfection. 1999 , 10, 123-32		115
1942	alpha-Gal epitopes on viral glycoproteins. 1999 , 32, 143-72		4
1941	Stable and efficient gene transfer into the mutant retinal pigment epithelial cells of the Mitf(vit) mouse using a lentiviral vector. 1999 , 18, 135-42		18
1940	Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. 1999 , 10, 2481-94		93
1939	Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. 1999 , 92, 185-96		68
1938	Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. 2000 , 95, 217-26		17

1937	Cochlear gene therapy: current perspectives. 1999 , 49 Suppl 1, S27-30		3
1936	Gene therapy for lung disease. 1999 , 20, 260-6		13
1935	Stable transfection of rat preproinsulin II gene into rat hematopoietic stem cells via recombinant adeno-associated virus. 1999 , 65, 2041-7		5
1934	Gene transfer to the brain: emerging therapeutic strategy in psychiatry?. 1999 , 45, 247-53		28
1933	Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. 1999 , 1, 433-8		
1932	Effets de galbrique virale. 1999 , 10, 287-299		
1931	Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. 1999 , 42, 1901-7		251
1930	Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. 2001 , Chapter 10, Unit 10.17C		199
1929	In pursuit of new developments for gene therapy of human diseases. 1999 , 68, 1-13		23
1928	Peripheral stem cells in bone marrow transplantation. Peripheral blood stem cell and gene therapy. 1999 , 12, 129-38		2
1927	Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. 1999 , 251, 156-65		68
1926	Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. <i>Experimental Neurology</i> , 1999 , 159, 47-64	5.7	33
1925	Lentiviral gene transfer to the nonhuman primate brain. <i>Experimental Neurology</i> , 1999 , 160, 1-16	5.7	168
1924	A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. 1999 , 31, 2037-47		120
1923	Methods for constructing and producing retroviral vectors. <i>Methods in Molecular Biology</i> , 2000 , 135, 495-508	1.4	
1922	Retroviral Vectors. 35-60		
1921	Lentiviral Vectors. 61-86		2
1920	Basic principles of gene transfer in hematopoietic stem cells. 1999 , 36, 1-19		3

1919	Emerging therapies for cystic fibrosis lung disease. 1999 , 115, 1120-6	38
1918	Translational control of gene expression using retroviral vectors with iron response elements. 1999 , 306, 225-41	
1917	Chapter 3.2.1 Gene transfer and therapy in the CNS. 1999 , 13, 379-395	
1916	New perspectives for cancer chemotherapy by genetic protection of haematopoietic cells. 1999 , 1999, 1-28	1
1915	Nuclear import of human immunodeficiency virus type-1 preintegration complexes. 1999 , 52, 275-99	85
1914	O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. 1999 , 36, 65-81	8
1913	Vectors in Gene Therapy. 77-112	4
1912	Lineage analysis with retroviral vectors. 2000 , 327, 118-45	20
1911	The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies. 2000 , 127, 267-97	11
1910	Eukaryotic gene transfer with liposomes: effect of differences in lipid structure. 2000 , 5, 197-220	16
1909	Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. 2000 , 2, 233-44	38
1908	Isolation of adult porcine islets of Langerhans. 2000 , 9, 297-305	44
1907	VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. 2000 , 2, 218-22	162
1906	Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. 2000 , 7, 364-77	18
1905	Production of High-Titer Lentiviral Vectors. 2000 , 26, 12.10.1	0
1904	Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. 2000 , 11, 2669-73	119
1903	Pluripotential mesenchymal cells repopulate bone marrow and retain osteogenic properties. 2000 , S134-45	45
1902	A VSV-G pseudotyped HIV vector mediates efficient transduction of human pulmonary artery smooth muscle cells. 2000 , 44, 1019-25	6

1901	The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS. 2000 , 11, 3973-7	55
1900	Advances in neurofibromatosis 2 (NF2): a workshop report. 2000 , 14, 63-106	26
1899	Progress with retroviral gene vectors. 2000 , 10, 185-202	59
1898	Novel bovine lentiviral vectors based on Jembrana disease virus. 2000 , 2, 176-85	46
1897	The application of a lentiviral vector for gene transfer in fetal human hepatocytes. 2000 , 2, 186-93	31
1896	Developments in gene therapy for muscular dystrophy. 2000 , 48, 223-38	53
1895	TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. 2000 , 45, 167-72	23
1894	Efficient expression of tetracycline-responsive gene after transfection of dentate gyrus neurons in vitro. 2000 , 60, 754-60	9
1893	Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. 2000 , 48, 27-38	152
1892	Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. 2000 , 2, 308-16	285
1891	Lentivirus-mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells. 2000 , 2, 317-25	19
1890	Gene therapy in wound repair and regeneration. 2000 , 8, 443-51	51
1889	IAP family proteins delay motoneuron cell death in vivo. 2000 , 12, 2059-67	65
1888	Haemophilias: advances towards genetic engineering replacement therapy. 2000 , 22, 313-23	1
1887	Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. 2000 , 178, 29-38	29
1886	Gene therapy of severe combined immunodeficiencies. 2000 , 178, 13-20	17
1885	Production of viral vectors for gene therapy applications. 2000 , 11, 205-8	62
1884	Efficient lentiviral transduction of liver requires cell cycling in vivo. 2000 , 24, 49-52	262

1883	Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. 2000 , 18, 527-32	168
1882	Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. 2000 , 25, 217-22	818
1881	HIV nuclear import: What's the flap?. 2000 , 6, 626-8	26
1880	Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures. 2000 , 7, 167-76	6
1879	Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. 2000 , 7, 991-6	29
1878	Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. 2000 , 7, 1286-92	43
1877	The macrophage - a novel system to deliver gene therapy to pathological hypoxia. 2000 , 7, 255-62	173
1876	Gene transfer into inflamed glomeruli using macrophages transfected with adenovirus. 2000 , 7, 263-70	34
1875	Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. 2000 , 7, 196-200	77
1874	Long-term phenotypic correction of rodent hemiparkinsonism by gene therapy using genetically modified myoblasts. 2000 , 7, 445-9	15
1873	Lentiviral vectors: turning a deadly foe into a therapeutic agent. 2000 , 7, 20-3	224
1872	Gene therapy in the CNS. 2000 , 7, 93-109	119
1871	Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. 2000 , 7, 596-604	79
1870	Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. 2000 , 7, 568-74	96
1869	Stem cell therapy and gene transfer for regeneration. 2000 , 7, 451-7	151
1868	Production and concentration of pseudotyped HIV-1-based gene transfer vectors. 2000 , 7, 910-3	151
1867	Growth factor enhanced retroviral gene transfer to the adult central nervous system. 2000 , 7, 1103-11	8
1866	Gene therapy and the two faces of HIV. 2000 , 7, 1351-2	3

1865	A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. 2000 , 7, 1656-63	58
1864	Cotransduction of nondividing cells using lentiviral vectors. 2000 , 7, 1562-9	29
1863	Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. 2000 , 7, 1613-23	180
1862	Gene therapy: trials and tribulations. 2000 , 1, 91-9	537
1861	Salivary glands as a model for craniofacial applications of gene transfer. 2000 , 29, 163-166	7
1860	Neurobiology of disease. 2000 , 10, 655-60	26
1859	Cellular transplants as sources for therapeutic agents. 2000 , 42, 3-27	19
1858	Gene therapy approaches for modulating bone regeneration. 2000 , 42, 121-38	74
1857	Ribozyme therapy for HIV infection. 2000 , 44, 71-8	40
1856	HIV protease as a target for retrovirus vector-mediated gene therapy. 2000 , 1477, 168-88	14
1855	Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. 2000 , 886, 82-98	280
1854	An adenoviral vector expressing the glucose transporter protects cultured striatal neurons from 3-nitropropionic acid. 2000 , 859, 21-5	15
1853	Gene therapy for autoimmune disorders. 2000 , 20, 334-46	21
1852	Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. <i>EMBO Journal</i> , 2000 , 19, 5884-94	13 122
1851	Construction of adenovirus for high level expression of small RNAs in mammalian cells. Application to a Bcl-2 ribozyme. 2000 , 15, 105-14	7
1850	Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiency. 2000 , 2, 22-31	12
1849	Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. 2000 , 18, 19-39	113
1848	Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. 2000 , 18, 352-9	50

1847	Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24. 2000 , 45, 18-23	9
1846	Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. 2000 , 95, 1237-1248	98
1845	Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to Moloney murine leukemia virusBased vectors. 2000 , 96, 3385-3391	37
1844	High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. 2000 , 96, 3392-3398	192
1843	Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. 2000 , 96, 3725-3733	97
1842	Therapeutic levels of human factor VIII and IX using HIV-1Based lentiviral vectors in mouse liver. 2000 , 96, 1173-1176	135
1841	Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. 2000 , 96, 1206-1214	123
1840	Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. 2000 , 96, 1309-1316	88
1839	Development of lentiviral vectors for gene therapy for human diseases. 2000 , 95, 2499-2504	196
1838	The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. 2000 , 96, 4103-4110	196
1837	Retroviral and lentiviral gene therapy for autoimmune disease. 2000 , 2, 167-88	1
1836	Metabolic Mechanisms and Diabetes Candidate Genes: Insights Gained from Genetic Engineering with Recombinant Adenoviruses. 2000 , 15, 61-84	2
1835	Viral Vectors I: Major Viral Vectors. 2000 , 1, S2-S16	1
1834	High-level expression of active HIV-1 integrase from a synthetic gene in human cells. 2000 , 14, 1389-1399	46
1833	Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. 2000 , 20, 5587-93	159
1832	Translation is not required To generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells. 2000 , 74, 11531-7	55
1831	ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. 2000 , 84, 1062-75	86
1830	. 2000 ,	0

1829 Gene Therapy of Pediatric Leukemia. **2000**, 20, 183-195

1828 Production of High-Titer Lentiviral Vectors. **2000**, 12, 4.21.1

6

1827 Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. **2000**, 97, 12227-32

127

1826 Separable mechanisms of attachment and cell uptake during retrovirus infection. **2000**, 74, 10790-5

39

1825 Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. **2000**, 74, 10778-84

89

1824 Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. **2000**, 74, 8307-15

114

1823 A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y. **2000**, 20, 3364-76

62

1822 Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. **2000**, 74, 1286-95

100

1821 Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo. **2000**, 275, 30408-16

27

1820 Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4+ and CD8+ T cells from HIV-1-infected individuals. **2000**, 165, 6620-6

39

1819 Lentiviral vectors for enhanced gene expression in human hematopoietic cells. **2000**, 2, 458-69

190

1818 Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. **2000**, 1, 533-44

68

1817 Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. **2000**, 1, 31-8

108

1816 Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. **2000**, 1, 574-80

45

1815 Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. **2000**, 1, 566-73

163

1814 Lentiviral vectors: regulated gene expression. **2000**, 1, 516-21

211

1813 Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. **2000**, 2, 404-14

138

1812 Recent developments in retroviral-mediated gene transduction. **2000**, 2, 423-34

24

1811	Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. 2000 , 11, 439-47	111
1810	Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir. 2000 , 11, 347-59	27
1809	Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. 2000 , 11, 1139-50	122
1808	Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. 2000 , 11, 2403-13	126
1807	Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. 2000 , 74, 1712-7	56
1806	Use of the NADH-quinone oxidoreductase (ND11) gene of <i>Saccharomyces cerevisiae</i> as a possible cure for complex I defects in human cells. 2000 , 275, 37774-8	62
1805	HIV RNA packaging and lentivirus-based vectors. 2000 , 48, 1-28	26
1804	Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. 2000 , 2, 71-80	142
1803	Globin gene therapy: one (seemingly) small vector change, one giant leap in optimism. 2000 , 2, 101-2	3
1802	Current status of viral gene therapy for brain tumours. 2000 , 9, 713-26	11
1801	A stable system for the high-titer production of multiply attenuated lentiviral vectors. 2000 , 2, 170-6	193
1800	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. 2000 , 241-265	19
1799	New gene and cell-based therapies for lung cancer. 2000 , 21, 463-72	3
1798	Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme. 2000 , 11, 715-27	13
1797	Inhibition of human immunodeficiency virus type 1 by packageable, multigenic antisense RNA. 2000 , 10, 141-51	4
1796	Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson's disease. 2000 , 11, 1529-41	20
1795	Progress in the use of gene transfer methods to treat genetic blood diseases. 2000 , 11, 2059-66	32
1794	Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector. 2000 , 11, 471-9	21

1793	Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. 2000 , 74, 3105-11	141
1792	Gene therapy for adenosine deaminase deficiency. 2000 , 51, 33-47	28
1791	Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. 2000 , 11, 2025-37	28
1790	Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. 2000 , 11, 1863-74	44
1789	Lentiviral and murine retroviral transduction of T cells for expression of human CD40 ligand. 2000 , 11, 323-32	20
1788	Development of multigene and regulated lentivirus vectors. 2000 , 74, 10589-99	99
1787	A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes. 2000 , 74, 3668-81	56
1786	Mechanism of interference mediated by human parainfluenza virus type 3 infection. 2000 , 74, 11792-9	27
1785	Human immunodeficiency virus type 1 Nef mediates sustained membrane expression of tumor necrosis factor and the related cytokine LIGHT on activated T cells. 2000 , 74, 9396-402	36
1784	High-level expression of active HIV-1 integrase from a synthetic gene in human cells. 2000 , 14, 1389-99	51
1783	Gene therapy for hemophilia. 2000 , 28, 1-24	9
1782	Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. 2000 , 74, 3431-9	50
1781	Genetic Engineering. 2000 ,	
1780	A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. 2000 , 74, 4839-52	172
1779	DNA-Dependent protein kinase is not required for efficient lentivirus integration. 2000 , 74, 11278-85	78
1778	Targeted deletion of Minpp1 provides new insight into the activity of multiple inositol polyphosphate phosphatase in vivo. 2000 , 20, 6496-507	50
1777	Emerging therapies in hepatology: liver-directed gene transfer and hepatocyte transplantation. 2000 , 167, 81-7	17
1776	Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. 2000 , 97, 3038-3043	51

1775	Dominant negative MyD88 proteins inhibit interleukin-1beta /interferon-gamma -mediated induction of nuclear factor kappa B-dependent nitrite production and apoptosis in beta cells. 2000 , 275, 37672-8		67
1774	Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells. 2000 , 74, 11911-8		41
1773	Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. 2000 , 74, 1258-66		30
1772	Development of a novel trans-lentiviral vector that affords predictable safety. 2000 , 2, 47-55		117
1771	Targeted and stable gene delivery into muscle cells by a two-step transfer system. 2000 , 275, 931-5		3
1770	Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. <i>Experimental Neurology</i> , 2000 , 164, 15-24	5.7	148
1769	Long-term expression driven by herpes simplex virus type-1 amplicons may fail due to eventual degradation or extrusion of introduced transgenes. <i>Experimental Neurology</i> , 2000 , 165, 58-65	5.7	9
1768	Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. 2000 , 299, 359-68		124
1767	In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. 2000 , 15, 199-214		121
1766	Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. 2000 , 130, 774-81		64
1765	Approach to ex vivo gene therapy in the treatment of Parkinson's disease. 2000 , 22 Suppl 1, S143-7		11
1764	Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. 2000 , 23, 183-90		55
1763	A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free HSV-1 vectors. 2000 , 84, 17-31		51
1762	Canine models for human genetic neurodegenerative diseases. 2000 , 24, 811-23		4
1761	Salivary glands as a model for craniofacial applications of gene transfer. 2000 , 29, 163-166		7
1760	Gene transfer to suppress bone marrow alkylation sensitivity. 2000 , 462, 107-20		10
1759	Strategies for cutaneous gene therapy. 2000 , 12, 198-203		2
1758	HIV-1 genome nuclear import is mediated by a central DNA flap. <i>Cell</i> , 2000 , 101, 173-85	56.2	725

1757	Biomedicine. Combating Parkinson's disease--step three. <i>Science</i> , 2000 , 290, 721-4	33.3	15
1756	Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. <i>Science</i> , 2000 , 290, 767-73	33.3	1076
1755	Lentiviral vectors. 2000 , 55, 599-609		84
1754	Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. 2000 , 11, 1385-95		91
1753	Advances in Research on Neurodegeneration. 2000 ,		
1752	Neural Transplantation Methods. 2000 ,		8
1751	The potential for therapy of immune disorders with gene therapy. 2000 , 47, 1389-407		8
1750	Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. 2000 , 11, 179-90		244
1749	Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. 2000 , 11, 1259-67		50
1748	Primary T lymphocytes as targets for gene therapy. 2000 , 9, 611-20		9
1747	FLT3 ligand preserves the uncommitted CD34+CD38- progenitor cells during cytokine prestimulation for retroviral transduction. 2000 , 9, 695-701		3
1746	Lentivirus vector mobilization and spread by human immunodeficiency virus. 2000 , 11, 2331-9		43
1745	Towards gene therapy of sickle cell disease. 2000 , 10, 1081-1093		
1744	Gene therapy in human cancer: report of human clinical trials. 2000 , 18, 740-6		4
1743	HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. 2000 , 16, 1771-6		21
1742	Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. 2000 , 11, 895-908		37
1741	Principles of gene therapy: potential applications in the treatment of cerebral ischaemia. 2000 , 14, 407-14		5
1740	A new class of HIV-1 integrase inhibitors: the 3,3,3', 3'-tetramethyl-1,1'-spirobi(indan)-5,5',6,6'-tetrol family. 2000 , 43, 2031-9		48

1739	GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES. 2000 , 20, 221-235	1
1738	Prospects for genetic therapy of cardiovascular disease. 2000 , 84, 199-213	17
1737	Viral vectors for gene transfer: a review of their use in the treatment of human diseases. 2000 , 60, 249-71	288
1736	Liver-directed gene therapy: promises, problems and prospects at the turn of the century. 2000 , 32, 238-52	41
1735	Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. 2000 , 11, 2315-29	43
1734	Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. 2000 , 11, 1901-9	77
1733	Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. 2000 , 1, 171-9	113
1732	Gene therapy: promises and problems. 2001 , 2, 177-211	237
1731	Prospects for gene therapy using haemopoietic stem cells. 2001 , 14, 823-34	1
1730	A new-generation stable inducible packaging cell line for lentiviral vectors. 2001 , 12, 981-97	133
1729	Sustainable systemic delivery via a single injection of lentivirus into human skin tissue. 2001 , 12, 1551-8	46
1728	High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector. 2001 , 19, 247-59	37
1727	Systematic determination of the packaging limit of lentiviral vectors. 2001 , 12, 1893-905	317
1726	Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. 2001 , 3, 97-104	147
1725	Gene therapy for prostate cancer: current status and future prospects. 2001 , 166, 1220-33	50
1724	Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene expression using a recombinant human immunodeficiency virus vector. 2001 , 12, 227-33	14
1723	Gene Therapy Protocols. 2001 ,	1
1722	Molecular Basis of Pancreas Development and Function. 2001 ,	1

1721	Lentivirus in the clinic. 2001 , 4, 511-2	22
1720	Isolation of multipotent neural precursors residing in the cortex of the adult human brain. <i>Experimental Neurology</i> , 2001 , 170, 48-62	5·7 236
1719	Gene transfer into neurons from hippocampal slices: comparison of recombinant Semliki Forest Virus, adenovirus, adeno-associated virus, lentivirus, and measles virus. 2001 , 17, 855-71	118
1718	Death of motoneurons induced by trophic deprivation or by excitotoxicity is not prevented by overexpression of SMN. 2001 , 8, 240-51	10
1717	Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. 2001 , 8, 433-46	136
1716	Viral vector-mediated gene therapy for Parkinson's disease. 2001 , 1, 496-506	6
1715	Approaches to gene therapy for human immunodeficiency virus infection. 2001 , 12, 1013-9	39
1714	[Gene therapy of X-linked severe combined immunologic deficiency (SCID-X1)]. 2001 , 49, 57-66	2
1713	Recombinant proteins for neurodegenerative diseases: the delivery issue. 2001 , 24, 533-40	65
1712	vaccins du futur : nouvelles technologies. 2001 , 14, 370-379	
1711	Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. 2001 , 7, 1245-54	197
1710	Factors influencing Islet of Langerhans graft function and monitoring. 2001 , 310, 3-16	78
1709	Molecular therapeutics of liver disease. 2001 , 5, 381-414, vi	11
1708	From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. 2001 , 33, 28-36	17
1707	Gene therapies for joint diseases. 2001 , 11, 10-6	1
1706	Gene therapy for lysosomal storage disorders. 2001 , 1, 857-67	33
1705	Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. 2001 , 12, 847-57	23
1704	Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. 2001 , 12, 77-86	54

1703	Current status of retroviral vector mediated gene transfer into human hematopoietic stem cells. 2001 , 41, 465-82	3
1702	Current status of retroviral vector mediated gene transfer into human hematopoietic stem cells. 2001 , 41, 1-18	4
1701	Gene therapy for rheumatoid arthritis. 2001 , 1, 971-8	13
1700	Specific growth factors and the healing of chronic wounds. 2001 , 10, 173-8	12
1699	Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. 2001 , 3, 438-48	140
1698	Gene therapy for diabetes. 2001 , 6, d175-191	6
1697	Cytokine gene-modified cell-based cancer vaccines. 2002 , 69, 233-57	7
1696	In Vivo Gene Transfer to Dopamine Neurons of Rat Substantia Nigra via the High-Affinity Neurotensin Receptor. 2001 , 7, 186-192	32
1695	Gene Therapy in Hemophilia: Clinical Trials Update. 2001 , 86, 172-177	29
1694	Current status of ribozymes as gene therapy agents for cancer. 2001 , 19, 495-509	16
1693	Feasibility of gene therapy for late neuronal ceroid lipofuscinosis. 2001 , 58, 1793-8	27
1692	Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. 2001 , 97, 114-21	131
1691	HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway. 2001 , 98, 541-7	61
1690	Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. 2001 , 98, 594-6	57
1689	HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. 2001 , 98, 823-9	92
1688	High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. 2001 , 98, 2664-72	102
1687	Packaging cell system for lentivirus vectors. Preparation and use. 2002 , 69, 275-302	11
1686	Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. 2001 , 4, 164-73	90

1685	Synthetic Genes for Prevention and Therapy: Implications on Safety and Efficacy of DNA Vaccines and Lentiviral Vectors. 147-168	
1684	The molecular genetics of lentiviral vectors--current and future perspectives. 2001 , 1, 237-51	39
1683	Lentivirus Vector Based on Simian Immunodeficiency Virus. 2002 , 351-360	
1682	Hammerhead Ribozymes. 2001 ,	
1681	Gene therapy. 2001 , 28, 175-92	8
1680	Hepatocyte transplantation: clinical and experimental application. 2001 , 79, 617-30	116
1679	Effect of deletion and the site of insertion in double copy anti-tat retroviral vectors: viral titres and production of anti-tat mRNA. 2001 , 146, 2191-200	2
1678	Clinical gene therapy in hematology: past and future. 2001 , 73, 162-9	21
1677	Targeted integration of foreign DNA into a defined locus on chromosome 19 in K562 cells using AAV-derived components. 2001 , 73, 469-475	21
1676	Approaches for gene delivery to the subfornical organ and magnocellular neurons. 2001 , 28, 602-9	1
1675	Gene therapy for genetic haematological disorders and immunodeficiencies. 2001 , 249, 379-90	39
1674	The use of nonhuman primate models to improve gene transfer into haematopoietic stem cells. 2001 , 249, 329-38	15
1673	Lentiviral-mediated gene transfer into haematopoietic stem cells. 2001 , 249, 339-43	24
1672	Retroviruses as tools to study the immune system. 2001 , 13, 496-504	28
1671	The beta-globin locus control region versus gene therapy vectors: a struggle for expression. 2001 , 59, 17-24	26
1670	Efficient, long-term transgene expression in <i>Xenopus laevis</i> dermal melanophores. 2001 , 14, 275-82	4
1669	Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. 2001 , 14, 1753-61	38
1668	EBV replicon vector system enhances transgene expression in vivo: applications to cancer gene therapy. 2001 , 3, 345-52	13

1667	Gene therapy for hemophilia. 2001 , 3, 3-20	38
1666	Gene therapy of severe combined immunodeficiencies. 2001 , 3, 201-6	38
1665	Transduction of CD34+ cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells. 2001 , 3, 311-20	25
1664	Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. 2001 , 3, 517-28	97
1663	Gene transfer into nonhuman primate hematopoietic stem cells: implications for gene therapy. 2001 , 19, 12-23	24
1662	Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells. 2001 , 19, 236-46	32
1661	Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. 2001 , 12, 1103-8	122
1660	Annotated References by Year. 2001 , 651-770	
1659	Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. 2001 , 279, 116-29	43
1658	The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. 2001 , 280, 243-52	39
1657	An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. 2001 , 282, 77-86	64
1656	Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. 2001 , 286, 475-82	41
1655	A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. 2001 , 291, 191-7	32
1654	Determinants for lentiviral infection of non-dividing cells. 2001 , 26, 35-49	27
1653	HIV-2 and SIV vector systems. 2001 , 26, 83-98	13
1652	Prospects for gene therapy using HIV-based vectors. 2001 , 26, 159-74	9
1651	HIV-1 vector systems. 2001 , 26, 51-81	11
1650	Safety considerations in vector development. 2001 , 26, 147-58	29

1649	NADH dehydrogenases: from basic science to biomedicine. 2001 , 33, 233-42	52
1648	Helper virus-free HSV-1 vectors packaged both in the presence of VSV G protein and in the absence of HSV-1 glycoprotein B support gene transfer into neurons in the rat striatum. 2001 , 7, 548-55	16
1647	Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. <i>EMBO Journal</i> , 2001 , 20, 3272-81	13 267
1646	Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. 2001 , 7, 33-40	1066
1645	In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. 2001 , 7, 310-6	176
1644	MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. 2001 , 7, 344-9	138
1643	A quantitative assay for HIV DNA integration in vivo. 2001 , 7, 631-4	594
1642	On the market. 2001 , 7, 634-635	
1641	The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. 2001 , 19, 446-50	173
1640	Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. 2001 , 7, 920-6	112
1639	Prostate-specific targeting using PSA promoter-based lentiviral vectors. 2001 , 8, 628-35	59
1638	Development of lentiviral vectors for antiangiogenic gene delivery. 2001 , 8, 879-89	52
1637	Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. 2001 , 8, 190-8	82
1636	Enhanced cationic liposome-mediated transfection using the DNA-binding peptide mu (mu) from the adenovirus core. 2001 , 8, 453-60	71
1635	A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component. 2001 , 8, 987-98	30
1634	A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. 2001 , 8, 1745-51	57
1633	Retroviral approaches to gene therapy of cystic fibrosis. 2001 , 953, 43-52	15
1632	Challenges and opportunities for development of an AIDS vaccine. 2001 , 410, 1002-7	163

1631	Summary Report of a Symposium: Genes and Gene Delivery for Diseases of Alcoholism. 2001 , 25, 1778-1800	6
1630	Targeting gene expression using HSV vectors. 2001 , 53, 155-70	17
1629	Xenoinfection of nonhuman primates by feline immunodeficiency virus. 2001 , 11, 1109-13	17
1628	Development of disabled, replication-defective gene transfer vectors from the Jembrana disease virus, a new infectious agent of cattle. 2001 , 80, 9-22	8
1627	Innovations in oral gene delivery: challenges and potentials. 2001 , 6, 92-101	33
1626	Analysis of gene transfer efficiency of retrovirus producer cell transplantation for in situ gene transfer to hematopoietic cells. 2001 , 29, 163-73	4
1625	Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. 2001 , 15, 2283-5	183
1624	Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. 2001 , 75, 8461-8	111
1623	The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: cotranslational RNA encapsidation and limitation of Gag protein confer specificity. 2001 , 75, 12058-69	76
1622	Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. 2001 , 75, 3626-35	267
1621	Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. 2001 , 75, 3791-801	77
1620	Recombinant Protein Drugs. 2001 ,	3
1619	Methods for studying pro- and antiapoptotic genes in nonimmortal cells. 2001 , 66, 197-227	32
1618	HIV-Based Vectors. 2002 , 259-274	1
1617	Survival effects of pigment epithelium-derived factor expressed by a lentiviral vector in rat cerebellar granule cells. 2001 , 23, 145-52	19
1616	Atrial natriuretic peptide gene transfer and regulated expression in primary vascular smooth muscle cells. 2001 , 1, 265-284	
1615	Gene therapy for cystic fibrosis. 2001 , 11, 1-15	6
1614	Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis. 2001 , 12, 401-13	22

1613	Helper plasmids for production of HIV-1-derived vectors. 2001 , 12, 2081-93	20
1612	Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. 2001 , 3, 485-90	32
1611	Lentiviral vector gene transfer into fetal rhesus monkeys (<i>Macaca mulatta</i>): lung-targeting approaches. 2001 , 4, 614-21	57
1610	Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. 2001 , 3, 319-22	109
1609	Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. 2001 , 3, 928-39	37
1608	Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems. 2001 , 3, 128-38	63
1607	Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. 2001 , 3, 602-12	51
1606	Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. 2001 , 4, 331-8	53
1605	Multigene lentiviral vectors based on differential splicing and translational control. 2001 , 4, 375-82	36
1604	Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells. 2001 , 3, 359-67	44
1603	Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. 2001 , 3, 14-23	35
1602	Selective CCR2B receptor antagonists based on indole-2-carboxylic acid. 2001 , 11, 145-148	2
1601	Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. 2001 , 10, 2109-21	331
1600	Locus control region of the human CD2 gene in a lentivirus vector confers position-independent transgene expression. 2001 , 75, 4641-8	24
1599	Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. 2001 , 75, 2857-65	71
1598	IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells. 2001 , 98, 9277-82	90
1597	Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. 2001 , 75, 5129-40	68
1596	Gene transfer as an approach to treating hemophilia. 2001 , 88, 137-44	47

1595	Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. 2001 , 75, 11747-54	31
1594	Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. 2001 , 167, 3114-22	279
1593	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. 2001 , 98, 5134-9	314
1592	Hematopoietic Stem Cell Protocols. 2001 ,	1
1591	Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. 2001 , 75, 3371-82	65
1590	Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides. 2001 , 98, 1471-6	43
1589	Rhesus monkey placental transgene expression after lentiviral gene transfer into preimplantation embryos. 2001 , 98, 10728-32	69
1588	Plasma membrane rafts play a critical role in HIV-1 assembly and release. 2001 , 98, 13925-30	550
1587	Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. 2001 , 75, 6086-94	105
1586	SOCS-1 protein prevents Janus Kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma. 2001 , 276, 25862-70	50
1585	Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. 2001 , 75, 4014-8	89
1584	Antibody-directed targeting of retroviral vectors via cell surface antigens. 2001 , 75, 8016-20	115
1583	Promotion of cell cycle progression by basic helix-loop-helix E2A. 2001 , 21, 6346-57	44
1582	Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. 2001 , 98, 11450-5	181
1581	Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. 2001 , 75, 5448-56	115
1580	Infection of nondividing cells by Rous sarcoma virus. 2001 , 75, 9526-31	66
1579	Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. 2001 , 75, 3547-55	65
1578	Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. 2001 , 75, 4129-38	101

1577	Properties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles. 2001 , 75, 548-55	18
1576	Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses. 2001 , 21, 1164-72	72
1575	Development of an avian leukosis-sarcoma virus subgroup A pseudotyped lentiviral vector. 2001 , 75, 9339-44	75
1574	Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. 2001 , 75, 2653-9	44
1573	Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. 2001 , 75, 4947-51	105
1572	Production of lentiviral vector supernatants and transduction of cellular targets. 2002 , 63, 275-86	
1571	Lentivirus and foamy virus vectors: novel gene therapy tools. 2001 , 1, 17-40	9
1570	Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. 2001 , 10, 3075-81	287
1569	VSV-G envelope glycoprotein forms complexes with plasmid DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA transfection. 2001 , 4, 232-8	15
1568	Retroviral-mediated transduction and clonal integration analysis of human hematopoietic stem and progenitor cells. 2002 , 63, 253-74	1
1567	Encapsulated cell implants as a novel treatment for Parkinson's disease. 2001 , 62, 279-88	1
1566	Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. 2001 , 4, 149-56	97
1565	Delivery of novel macromolecular drugs against HIV-1. 2001 , 1, 949-70	10
1564	N-substituted acetonitrile inhibitors of cathepsin L. 2001 , 11, 149-152	
1563	Genetic modification of human trabecular meshwork with lentiviral vectors. 2001 , 12, 2109-19	70
1562	Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. 2001 , 12, 607-17	68
1561	Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. 2001 , 12, 811-21	86
1560	Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. 2001 , 12, 2203-13	60

1559	Stable transduction with lentiviral vectors and amplification of immature hematopoietic progenitors from cord blood of preterm human fetuses. 2001 , 12, 377-89	30
1558	Long-term engraftment of nonobese diabetic/severe combined immunodeficient mice with human CD34+ cells transduced by a self-inactivating human immunodeficiency virus type 1 vector. 2001 , 12, 1079-89	26
1557	Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems. 2002 , 13, 1293-303	17
1556	Cationic liposome-mediated GDNF gene transfer after spinal cord injury. 2002 , 19, 1081-90	28
1555	alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. 2002 , 99, 10813-8	439
1554	Lentiviral gene transduction of kidney. 2002 , 13, 407-14	43
1553	Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. 2002 , 99, 2140-5	457
1552	Viral approaches to cancer gene therapy. 2002 , 12, 369-378	5
1551	HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. 2002 , 13, 1806-15	124
1550	A novel secreted splice variant of vascular endothelial cell growth inhibitor. 2002 , 16, 742-4	85
1549	In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. 2002 , 76, 1496-504	50
1548	Transduction of interphase cells by avian sarcoma virus. 2002 , 76, 5422-34	61
1547	Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells. 2002 , 99, 3651-6	14
1546	Inducible expression of the deltaNGFr/F12Nef fusion protein as a new tool for anti-human immunodeficiency virus type 1 gene therapy. 2002 , 13, 1751-66	5
1545	Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. 2002 , 6, 19-29	110
1544	Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. 2002 , 13, 1305-16	34
1543	Gene therapy for prostate cancer. 2002 , 2, 309-21	12
1542	Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. 2002 , 76, 9103-11	84

1541	Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. 2002 , 76, 1488-95	156
1540	Transepithelial transport of HIV-1 by M cells is receptor-mediated. 2002 , 99, 9410-4	80
1539	Effects of varying sequence similarity on the frequency of repeat deletion during reverse transcription of a human immunodeficiency virus type 1 vector. 2002 , 76, 7897-902	45
1538	Lentivirus vector-mediated gene transfer to cardiomyocytes. <i>Methods in Molecular Biology</i> , 2003 , 219, 53-70	1.4 7
1537	Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. 2002 , 277, 1770-9	56
1536	Cardiac Cell and Gene Transfer. 2002 ,	
1535	Highly efficient gene transfer into primate embryonic stem cells with a simian lentivirus vector. 2002 , 6, 162-8	39
1534	Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency. 2002 , 6, 824-9	8
1533	Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. 2002 , 5, 509-16	95
1532	Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. 2002 , 6, 199-209	112
1531	Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. 2002 , 5, 547-54	105
1530	Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. 2002 , 5, 242-51	183
1529	Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. 2002 , 5, 141-53	57
1528	Treatment of chronic wounds: state of the art and future concepts. 2002 , 172, 105-17	50
1527	Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. 2002 , 76, 1004-14	166
1526	Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. 2002 , 76, 3739-47	202
1525	Restriction of lentivirus in monkeys. 2002 , 99, 11920-5	248
1524	Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. 2002 , 30, e113	84

1523	Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. 2002 , 46, 3292-7	48
1522	Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. 2002 , 76, 7544-53	34
1521	HIV-1-derived lentiviral vectors. 2002 , 261, 31-52	56
1520	Biosafety issues in lentivector production. 2002 , 261, 123-41	11
1519	RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes. 2002 , 76, 11853-65	46
1518	cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells. 2002 , 51, 1805-14	46
1517	Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. 2002 , 277, 32036-45	62
1516	Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein. 2002 , 5, 762-9	29
1515	Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA. 2002 , 346, 92-105	53
1514	Gene transfer into hematopoietic stem cells using lentiviral vectors. 2002 , 2, 45-55	42
1513	Brain engraftment of autologous macrophages transduced with a lentiviral flap vector: an approach to complement brain dysfunctions. 2002 , 9, 46-52	16
1512	Development of gene therapy for hematopoietic stem cells using lentiviral vectors. 2002 , 16, 563-9	34
1511	In vivo gene delivery to synovium by lentiviral vectors. 2002 , 5, 397-404	91
1510	Viral vector-mediated gene expression in olfactory ensheathing glia implants in the lesioned rat spinal cord. 2002 , 9, 135-46	107
1509	Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. 2002 , 76, 11236-44	65
1508	Evaluation of Tat-encoding bicistronic human immunodeficiency virus type 1 gene transfer vectors in primary canine bone marrow mononuclear cells. 2002 , 76, 7334-42	3
1507	Current issues in cochlear gene transfer. 2002 , 7, 146-51	32
1506	Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. 2002 , 76, 10356-64	155

1505	Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. 2002 , 76, 1510-5	41
1504	Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. 2002 , 157, 417-27	177
1503	Poly(ADP-ribose) polymerase 1 is not strictly required for infection of murine cells by retroviruses. 2002 , 76, 11904-10	26
1502	Evaluation of drug resistance in HIV infection. 2002 , 58, 157-202	2
1501	Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. 2002 , 46, 1896-905	1310
1500	Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. 2002 , 99, 15590-5	95
1499	In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. 2002 , 76, 9378-88	123
1498	Matrix fibronectin increases HIV stability and infectivity. 2002 , 168, 5722-9	25
1497	Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. 2002 , 76, 12087-96	132
1496	Expression from Second-Generation Feline Immunodeficiency Virus Vectors Is Impaired in Human Hematopoietic Cells. 2002 , 6, 645-652	1
1495	New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1. 2002 , 169, 2762-71	24
1494	Oncoretroviral and lentiviral vector-mediated gene therapy. 2002 , 346, 573-89	28
1493	Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. 2002 , 22, 5912-22	113
1492	Retrovirus vectors. 2000 , 465, 23-35	1
1491	Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. 2002 , 99, 8295-300	81
1490	K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. 2002 , 76, 802-16	169
1489	Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. 2002 , 13, 75-82	108
1488	Gene therapy of human disease. 2002 , 81, 69-86	33

1487	Efficient transduction of pancreatic islets by feline immunodeficiency virus vectors1. 2002 , 74, 299-306	23
1486	Novel therapeutic approaches in sickle cell disease. 2002 , 2002, 10-34	8
1485	Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. 2002 , 100, 813-22	222
1484	Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. 2002 , 99, 399-408	122
1483	Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. 2002 , 99, 709-12	67
1482	Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. 2002 , 99, 1902-8	146
1481	Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. 2002 , 99, 2342-50	85
1480	Biosafety in Handling Gene Transfer Vectors. 2002 , 35, 12.1.1	
1479	Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. 2002 , 100, 4381-90	52
1478	Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. 2002 , 100, 3147-54	34
1477	Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. 2002 , 100, 3960-7	88
1476	Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. 2002 , 100, 823-32	249
1475	Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. 2002 , 100, 4129-38	85
1474	Gene transfer methods for transplantation. 2002 , 346, 199-224	3
1473	Transduction of a gene expression cassette using advanced generation lentiviral vectors. 2002 , 346, 514-29	64
1472	Human immunodeficiency virus type 1-based vectors for gene delivery to human hematopoietic stem cells. 2003 , 76, 467-92	3
1471	Lentiviral Transfer of the LacZ Gene into Human Endothelial Cells and Human Bone Marrow Mesenchymal Stem Cells. 2002 , 11, 481-488	37
1470	Maximal Lentivirus-Mediated Gene Transfer and Sustained Transgene Expression in Human Hematopoietic Primitive Cells and Their Progeny. 2002 , 6, 673-677	

1469	Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic Cells. 2002 , 6, 615-626	5
1468	Gene transfer to airway epithelia using feline immunodeficiency virus-based lentivirus vectors. 2002 , 346, 500-14	3
1467	Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic Cells. 2002 , 6, 615-626	88
1466	Developments in cochlear gene therapy. 2002 , 61, 28-33	4
1465	Development of simian retroviral vectors for gene delivery. 2003 , 76, 353-65	
1464	Neuroprotective gene therapy for Parkinson's disease. 2002 , 2, 451-83	20
1463	Gene delivery using herpes simplex virus vectors. 2002 , 21, 915-36	75
1462	Mechanisms that regulate silencing of gene expression from retroviral vectors. 2002 , 11, 449-56	32
1461	Ex vivo and in vitro studies of transgene expression in rat astrocytes transduced with lentiviral vectors. <i>Experimental Neurology</i> , 2002 , 173, 22-30	5:7 33
1460	The potential for gene therapy in the treatment of autoimmune disease. 2002 , 104, 204-16	19
1459	Gene therapy and reproductive medicine. 2002 , 77, 645-57	18
1458	Production of trans-lentiviral vector with predictable safety. 2003 , 76, 449-65	19
1457	Generation of HIV-1-based lentiviral vector particles. 2002 , Chapter 16, Unit 16.22	12
1456	Overview of the HIV-1 Lentiviral Vector System. 2002 , Chapter 16, Unit 16.21	14
1455	Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. 2002 , 109, 988-94	32
1454	Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. 2002 , 13, 841-53	121
1453	Virus-based gene delivery systems. 2002 , 41, 901-11	58
1452	Molecular biology of lentivirus-mediated gene transfer. 2002 , 261, 1-30	13

1451	Viral Vectors for Gene Therapy. 2002 ,	1
1450	Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. 2002 , 13, 653-63	47
1449	Biotechnology in Animal Husbandry. 2002 ,	2
1448	Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. 2002 , 13, 261-73	27
1447	Gene transfer to salivary glands. 2002 , 213, 93-146	63
1446	Main Sessions. 2002 , 81, S67-S74	
1445	High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. 2002 , 13, 803-13	409
1444	Gene therapy for Parkinson's disease. 2002 , 2, 151-61	4
1443	Human immunodeficiency virus type 2 (HIV-2) vector-mediated in vivo gene transfer into adult rabbit retina. 2002 , 24, 196-201	21
1442	Gene therapy in infants with severe combined immunodeficiency. 2002 , 16, 229-39	12
1441	Generation of HIV-1 derived lentiviral vectors. 2002 , 346, 454-65	162
1440	Gene technology and tissue engineering. 2002 , 11, 93-9	
1439	A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. 2002 , 13, 1793-807	52
1438	Lentiviral vector transduction of male germ line stem cells in mice. 2002 , 524, 111-5	64
1437	Gene therapy for genetic and acquired retinal diseases. 2002 , 47, 449-69	28
1436	Efficient gene transduction to cultured hepatocytes by HIV-1 derived lentiviral vector. 2002 , 34, 1431-3	16
1435	Lentiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection. 2002 , 42, 551-8	29
1434	Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. 2002 , 5, 528-37	181

1433	The promise of biomarkers in cancer screening and detection. 2002 , 8, 288-93	82
1432	Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. 2002 , 12 Suppl 1, S23-9	67
1431	Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal. 2002 , 105, 86-97	41
1430	HIV vaccine strategies. 2002 , 20, 1945-7	49
1429	Vectors derived from simian immunodeficiency virus (SIV). 2002 , 84, 1161-71	23
1428	Lentiviral vectors for gene delivery into cells. 2002 , 21, 937-51	72
1427	Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. 2002 , 277, 38884-94	260
1426	Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. <i>Science</i> , 2002 , 295, 868-72	333 1674
1425	Gene therapy for the central nervous system in the lysosomal storage disorders. 2002 , 20, 879-901	13
1424	Viruses in the treatment of brain tumors. 2002 , 12, 553-70	7
1423	Pharmacological, Cell, and Gene Therapy Strategies to Promote Spinal Cord Regeneration. 2002 , 11, 593-613	51
1422	The Advent of Lentiviral Vectors: Prospects for Cancer Therapy. 2002 , 109-124	1
1421	Gene Transfer to Muscle and Spinal Cord Using Herpes Simplex Virus-Based Vectors. 2002 , 179-200	1
1420	4. Neue tumortheraeutische Ansätze und ihre klinische Bedeutung. 2002 , 56, 131-189	
1419	Adeno-Associated Viral Delivery of GDNF Promotes Recovery of Dopaminergic Phenotype following a Unilateral 6-Hydroxydopamine Lesion. 2002 , 11, 215-227	31
1418	Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. 2002 , 22, 10251-66	123
1417	References. 2002 , 177-248	
1416	Maximal Lentivirus-Mediated Gene Transfer and Sustained Transgene Expression in Human Hematopoietic Primitive Cells and Their Progeny. 2002 , 6, 673-677	34

1415	Expression from Second-Generation Feline Immunodeficiency Virus Vectors Is Impaired in Human Hematopoietic Cells. 2002 , 6, 645-652	25
1414	Adeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy. 2000 , 465, 457-66	8
1413	Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase. 2002 , 103, 75-88	11
1412	Efficient transfer of HTLV-1 tax gene in various primary and immortalized cells using a flap lentiviral vector. 2002 , 105, 133-40	12
1411	Nonhuman primate transgenesis: progress and prospects. 2002 , 20, 479-84	8
1410	New class of HIV integrase inhibitors that block viral replication in cell culture. 2002 , 12, 1169-77	90
1409	Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy. 2002 , 30, 108-15	4
1408	Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. 2002 , 67, 363-71	67
1407	Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. 2002 , 69, 955-65	101
1406	Single-step, multiple retroviral transduction of human T cells. 2002 , 4, 27-37	38
1405	High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. 2002 , 4, 161-9	9
1404	Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. 2002 , 4, 229-39	18
1403	Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. 2002 , 4, 347-55	16
1402	Hematopoietic stem cell gene therapy. 2002 , 75, 228-36	21
1401	Selective expansion of transduced cells for hematopoietic stem cell gene therapy. 2002 , 76, 299-304	7
1400	An RCAS-TVA-based approach to designer mouse models. 2002 , 13, 543-7	56
1399	UW solution: a promising tool for cryopreservation of primarily isolated rat hepatocytes. 2002 , 9, 742-9	23
1398	Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. 2002 , 97, 348-58	75

1397	Gene transfer mediated by different viral vectors following direct cannulation of mouse submandibular salivary glands. 2002 , 110, 254-60	24
1396	Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. 2002 , 13, 429-36	78
1395	Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells. 2002 , 8, 255-60	12
1394	Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. 2002 , 119, 365-9	63
1393	In vivo gene transfer to kidney by lentiviral vector. 2002 , 61, S32-6	20
1392	An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. 1997 , 68, 1792-803	57
1391	Insulin-enhanced liposome-mediated gene transfer into a gastric carcinoma cell line. 2002 , 29, 544-8	2
1390	Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. 2002 , 9, 715-24	42
1389	Gene transduction efficiency in cells of different species by HIV and EIAV vectors. 2002 , 9, 932-8	66
1388	Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. 2002 , 9, 889-97	38
1387	Titerting lentiviral vectors: comparison of DNA, RNA and marker expression methods. 2002 , 9, 1155-62	257
1386	Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS. 2002 , 9, 1291-301	54
1385	Efficient marking of neural stem cell-derived neurons with a modified murine embryonic stem cell virus, MESV2. 2002 , 9, 1044-8	4
1384	Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. 2002 , 9, 1464-71	50
1383	Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. 2002 , 9, 1708-14	71
1382	Lentiviruses in gene therapy clinical research. 2002 , 9, 1730-4	87
1381	Optimized lentiviral transduction of erythroid precursors from healthy adults and patients with myelodysplastic syndromes. 2002 , 16, 1319-23	5
1380	Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. 2002 , 16, 1974-83	42

1379	Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. 2002 , 20, 53-7	60
1378	Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. 2002 , 20, 256-63	28
1377	Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. 2002 , 20, 895-900	54
1376	Therapeutic applications for hematopoietic stem cell gene transfer. 2002 , 3, 318-21	38
1375	Latest developments and in vivo use of the Tet system: ex vivo and in vivo delivery of tetracycline-regulated genes. 2002 , 13, 448-52	78
1374	Genomic medicine: exploring the basis of a new approach to endocrine hypertension. 2002 , 970, 177-92	3
1373	Transduction of umbilical cord blood CD34+ NOD/SCID-repopulating cells by simian foamy virus type 1 (SFV-1) vector. 2002 , 302, 229-35	23
1372	A minimal genome simian foamy virus type 1 vector system with efficient gene transfer. 2002 , 302, 236-44	10
1371	Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector. 2002 , 304, 10-23	11
1370	Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. 2002 , 6, 219-26	219
1369	Cancer gene therapy: Part 1. Vector development and regulation of gene expression. 2002 , 14, 3-16	8
1368	Lentiviral expression of HIV-1 Vpr induces apoptosis in human neurons. 2002 , 8, 86-99	51
1367	Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction. 2002 , 26, 131-41	10
1366	Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. 2003 , 37, 994-1005	74
1365	A highly efficient, stable, and rapid approach for ex vivo human liver gene therapy via a FLAP lentiviral vector. 2003 , 38, 114-22	43
1364	The HTLV-1 tax oncoprotein attenuates DNA damage induced G1 arrest and enhances apoptosis in p53 null cells. 2003 , 305, 229-39	45
1363	High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. 2003 , 21, 111-7	243
1362	Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation. 2003 , 21, 472-80	21

1361	Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. 2003 , 14, 263-76	39
1360	Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. 2003 , 101, 1727-33	62
1359	Ectopic expression of the beta-cell specific transcription factor Pdx1 inhibits glucagon gene transcription. 2003 , 46, 810-21	36
1358	Expression of human clotting factor IX mediated by recombinant lentiviral vector in cultured cells and hemophilia B mice. 2003 , 48, 2196-2200	
1357	Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. 2003 , 81, 310-20	19
1356	Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. 2003 , 81, 801-10	16
1355	Regulation of the expression of the prostate-specific antigen by claudin-7. 2003 , 194, 187-97	36
1354	Current status and future prospects of gene therapy technologies toward the treatment of intractable skin diseases. 2003 , 295 Suppl 1, S63-6	2
1353	Genetic manipulation of primate embryonic and hematopoietic stem cells with simian lentivirus vectors. 2003 , 13, 106-10	12
1352	Gene therapy in immune-mediated diseases of the eye. 2003 , 22, 277-93	14
1351	Taking the good out of the bad: lentiviral-based gene therapy of the hemoglobinopathies. 2003 , 21, 513-26	3
1350	Gene transfer in purified human hematopoietic peripheral-blood stem cells by means of electroporation without prestimulation. 2003 , 141, 138-49	20
1349	Sequences within both the 5' untranslated region and the gag gene are important for efficient encapsidation of Mason-Pfizer monkey virus RNA. 2003 , 309, 166-78	18
1348	Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. 2003 , 314, 74-83	14
1347	Roles of host cell factors in circularization of retroviral dna. 2003 , 314, 460-7	95
1346	Localization of transfected B7-1 (CD80) DNA in human melanoma cells after particle-mediated gene transfer. 2003 , 144, 106-11	2
1345	Rapid in vivo isolation of gene expression elements using an HSV amplicon system. 2003 , 113, 1-12	2
1344	Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. 2003 , 1640, 1-24	48

1343	Lentiviral vectors for gene delivery to normal and demyelinated white matter. 2003 , 42, 59-67	23
1342	HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro. <i>Journal of Medical Virology</i> , 2003 , 71, 173-82	19.7 18
1341	Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. 2003 , 5, 654-67	145
1340	Rational development of a HIV-1 gene therapy vector. 2003 , 5, 829-838	31
1339	Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. 2003 , 5, 1009-17	32
1338	Potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease. 2003 , 54 Suppl 6, S103-9	6
1337	Development and retroviral transduction of porcine neonatal pancreatic islet cells in monolayer culture. 2003 , 45, 39-50	11
1336	Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. 2003 , 1, 2300-11	25
1335	Optimal modes and targets of gene therapy in transplantation. 2003 , 196, 161-75	10
1334	An efficient gene transduction system for studying gene function in primary human dermal fibroblasts and epidermal keratinocytes. 2003 , 28, 193-9	31
1333	Hematopoietic stem cell gene therapy: progress toward therapeutic targets. 2003 , 32, 1-7	24
1332	Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. 2003 , 10, 689-95	25
1331	Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. 2003 , 10, 764-70	46
1330	Efficient transgenesis in farm animals by lentiviral vectors. 2003 , 4, 1054-60	220
1329	Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. 2003 , 10, 219-26	69
1328	Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. 2003 , 10, 818-21	61
1327	Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: a preclinical safety study in adult rats. 2003 , 10, 1161-9	27
1326	Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. 2003 , 10, 1234-40	65

1325	HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. 2003 , 10, 1321-7	13
1324	Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats. 2003 , 10, 1503-11	70
1323	Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. 2003 , 10, 1917-25	34
1322	UCP3 protein regulation in human skeletal muscle fibre types I, IIa and IIx is dependent on exercise intensity. 2003 , 550, 855-61	41
1321	A transgenic mouse model of the ubiquitin/proteasome system. 2003 , 21, 897-902	194
1320	A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. 2003 , 33, 401-6	1327
1319	Induction of an interferon response by RNAi vectors in mammalian cells. 2003 , 34, 263-4	840
1318	Convergent evolution of gene circuits. 2003 , 34, 264-6	158
1317	Gene transfer as a tool to induce therapeutic vascular growth. 2003 , 9, 694-701	346
1316	Dissecting HIV-1 through RNA interference. 2003 , 3, 851-8	61
1315	Killing the messenger: short RNAs that silence gene expression. 2003 , 4, 457-67	960
1314	Neuroprotective gene therapy against acute neurological insults. 2003 , 4, 61-9	52
1313	Development of gene therapy for hemoglobin disorders. 2003 , 996, 101-11	9
1312	Efficient characterization of retro-, lenti-, and foamyvector-transduced cell populations by high-accuracy insertion site sequencing. 2003 , 996, 112-21	20
1311	Genetic therapy for HIV/AIDS. 2003 , 3, 951-63	10
1310	Molecular biology and gene therapy in the treatment of chronic pain. 2003 , 14, 419-35	7
1309	Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. 2003 , 8, 666-73	78
1308	Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. 2003 , 8, 196-206	146

1307	In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. 2003 , 144, 5578-84		241
1306	High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes. 2003 , 14, 385-91		16
1305	Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. 2003 , 14, 1799-807		100
1304	Gene delivery by lentivirus vectors an overview. <i>Methods in Molecular Biology</i> , 2004 , 246, 367-90	1.4	38
1303	Detection and selection of lentiviral vector-transduced cells. <i>Methods in Molecular Biology</i> , 2003 , 229, 69-85	1.4	3
1302	Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. 2003 , 14, 67-77		64
1301	Comparison of multi-lineage cells from human adipose tissue and bone marrow. 2003 , 174, 101-9		970
1300	Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. <i>EMBO Journal</i> , 2003 , 22, 3675-85	13	141
1299	Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. 2003 , 197, 633-42		908
1298	Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. 2003 , 77, 8196-206		82
1297	Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. 2003 , 8, 62-71		144
1296	Retroviral insertional mutagenesis: tagging cancer pathways. 2003 , 88, 53-99		102
1295	ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes. 2003 , 163, 243-51		54
1294	Regulating gene expression using self-inactivating lentiviral vectors containing the mifepristone-inducible system. 2003 , 323, 67-77		34
1293	Gene therapy with viral vectors. 2003 , 43, 413-39		211
1292	Vectors for cardiovascular gene therapy. 2003 , 35, 731-3		7
1291	In vivo fluorescent labeling of corneal wound healing fibroblasts. 2003 , 76, 361-71		17
1290	Inhibitory and enhancing effects of insertion of central polypurine tract sequence on gene expression with vectors derived from human immunodeficiency virus type 1. 2003 , 302, 489-95		2

1289	Successful lentivirus-based delivery of NLS-LACZ gene into porcine hepatocytes. 2003 , 35, 435-6	3
1288	Successful lentivirus-based delivery of a LacZ gene into human endothelial cells. 2003 , 35, 499-500	6
1287	Sequences within the gag gene of feline immunodeficiency virus (FIV) are important for efficient RNA encapsidation. 2003 , 93, 199-209	22
1286	The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors. 2003 , 31, 28-37	26
1285	Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option?. 2003 , 6, 57-69	4
1284	Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. 2003 , 14, 497-507	112
1283	Comparison of transfection conditions for a lentivirus vector produced in large volumes. 2003 , 14, 1287-96	54
1282	Cytokine gene transfer. 2003 , 1335-1348	
1281	Multilineage cells from adipose tissue as gene delivery vehicles. 2003 , 14, 59-66	127
1280	Lentivirus Gene Engineering Protocols. 2003 ,	7
1279	Efficient lentiviral vectors for short hairpin RNA delivery into human cells. 2003 , 14, 1207-12	79
1278	Gene Delivery to Mammalian Cells. 2003 ,	
1277	Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. 2003 , 14, 1441-9	49
1276	Stable genetic modification of human embryonic stem cells by lentiviral vectors. 2003 , 7, 281-7	217
1275	Gene therapy for malignant brain tumors. 2003 , 3, 685-701	2
1274	Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells. 2003 , 14, 1727-39	13
1273	Construction and analysis of cells lacking the HMGA gene family. 2003 , 31, 5025-32	29
1272	Human immunodeficiency virus type 1 genetic recombination is more frequent than that of Moloney murine leukemia virus despite similar template switching rates. 2003 , 77, 4577-87	68

1271	Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. 2003 , 17, 2014-24	124
1270	Human immunodeficiency virus type 1 DNA nuclear import and integration are mitosis independent in cycling cells. 2003 , 77, 13412-7	52
1269	KSHV vFLIP binds to IKK-gamma to activate IKK. 2003 , 116, 3721-8	198
1268	Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. 2003 , 107, 2375-82	80
1267	Lentivirus-mediated transduction of connexin cDNAs shows level- and isoform-specific alterations in insulin secretion of primary pancreatic beta-cells. 2003 , 116, 2285-94	41
1266	Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. 2003 , 77, 2539-49	93
1265	Human T-cell leukemia virus-I tax oncoprotein functionally targets a subnuclear complex involved in cellular DNA damage-response. 2003 , 278, 37736-44	82
1264	The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. 2003 , 100, 11517-22	38
1263	Suppression of gene expression by a cell-permeable Tet repressor. 2003 , 31, e152	9
1262	Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. 2003 , 100, 4778-83	89
1261	Identification of a novel proliferation-inducing determinant using lentiviral expression cloning. 2003 , 31, e113	8
1260	The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. 2003 , 77, 9439-50	35
1259	Gene transfer strategies for correction of lysosomal storage disorders. 2003 , 110, 71-85	21
1258	Lentivirus vectors incorporating the immunoglobulin heavy chain enhancer and matrix attachment regions provide position-independent expression in B lymphocytes. 2003 , 77, 7341-51	39
1257	G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. 2003 , 77, 2550-8	55
1256	Hematopoietic stem and progenitor cells. <i>Methods in Molecular Biology</i> , 2003 , 229, 117-30	1.4
1255	Neurosciences at the Postgenomic Era. 2003 ,	
1254	Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. 2003 , 12, 221-8	139

1253	Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. 2003 , 77, 8957-61	633
1252	High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. 2003 , 77, 11193-200	119
1251	Virus-based vectors for gene expression in mammalian cells: Retrovirus. 2003 , 38, 231-250	3
1250	Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. 2003 , 14, 509-19	102
1249	Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. 2003 , 14, 1489-94	22
1248	Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. 2003 , 14, 1127-37	31
1247	Current status of gene therapy for inherited lung diseases. 2003 , 65, 585-612	58
1246	Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication-competent viruses. 2003 , 8, 830-9	54
1245	Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. 2003 , 8, 332-41	82
1244	HIV vector production mediated by Rev protein transduction. 2003 , 8, 324-31	9
1243	Development of an HIV-based cDNA expression cloning system. 2003 , 8, 167-73	6
1242	Characterization and detection of artificial replication-competent lentivirus of altered host range. 2003 , 8, 118-29	30
1241	Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector. 2003 , 8, 600-10	25
1240	A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. 2003 , 8, 804-12	14
1239	Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. 2003 , 7, 782-9	40
1238	Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. 2003 , 7, 317-24	49
1237	Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. 2003 , 8, 895-902	24
1236	Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. 2003 , 7, 801-10	34

1235	Global analysis of cellular transcription following infection with an HIV-based vector. 2003 , 8, 674-87	31
1234	The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. 2003 , 8, 314-23	40
1233	Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. 2003 , 14, 1089-105	43
1232	A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. 2003 , 77, 2964-71	33
1231	Replicating parvoviruses that target colon cancer cells. 2003 , 77, 6683-91	42
1230	Detection and titration of lentivirus vector preparations. <i>Methods in Molecular Biology</i> , 2003 , 229, 57-68 1.4	1
1229	Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. 2003 , 77, 4685-94	110
1228	Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders. 2003 , 55, 3-64	8
1227	A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes. 2003 , 14, 1579-85	20
1226	A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. 2003 , 100, 1844-8	506
1225	Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of Gag-Gag interactions and membrane association. 2003 , 77, 11651-60	34
1224	Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. 2003 , 47, 501-8	11
1223	Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. 2003 , 12, 2827-36	70
1222	Lentiviral vector: a useful tool for transduction of human liver endothelial cells. 2003 , 49, 635-40	9
1221	Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. 2003 , 2, 179-84	44
1220	SIV Vectors. <i>Methods in Molecular Biology</i> , 2003 , 229, 233-49	1.4 4
1219	FIV Vectors. <i>Methods in Molecular Biology</i> , 2003 , 229, 251-71	1.4 38
1218	Genetically modified NT2N human neuronal cells mediate long-term gene expression as CNS grafts in vivo and improve functional cognitive outcome following experimental traumatic brain injury. 2003 , 62, 368-80	76

1217	Lentiviral transduction of human dendritic cells. <i>Methods in Molecular Biology</i> , 2004 , 246, 451-9	1.4	13
1216	Small- to large-scale production of lentivirus vectors. <i>Methods in Molecular Biology</i> , 2003 , 229, 43-55	1.4	36
1215	Airway epithelia. <i>Methods in Molecular Biology</i> , 2003 , 229, 181-96	1.4	
1214	Hybrid lentivirus vectors. <i>Methods in Molecular Biology</i> , 2003 , 229, 273-84	1.4	1
1213	Cryopreservation of primarily isolated porcine hepatocytes with UW solution. 2003 , 12, 607-16		30
1212	Gene therapy for neurological disease. 2003 , 3, 815-28		14
1211	Use of lentiviral vectors for delivery of small interfering RNA. 2003 , 2, 206-10		41
1210	Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells. 2003 , 77, 9295-304		38
1209	Gene Therapy for Pituitary Tumors. 2003 , 13, 351-357		
1208	Cochlear gene therapy. 2003 , 24, 342-8		24
1207	Delivery using herpes simplex virus: an overview. <i>Methods in Molecular Biology</i> , 2004 , 246, 257-99	1.4	30
1206	Lentiviral vectors for the delivery of DNA into mammalian cells. <i>Methods in Molecular Biology</i> , 2004 , 246, 391-411	1.4	9
1205	Dorsal root ganglia sensory neurons. <i>Methods in Molecular Biology</i> , 2003 , 229, 155-67	1.4	
1204	Lentiviral vectors. 2003 , 55, 111-22		6
1203	Virus-based vectors for gene expression in mammalian cells: Lentiviruses. 2003 , 251-264		3
1202	Efficient production of human FVIII in hemophilic mice using lentiviral vectors. 2003 , 7, 623-31		97
1201	Production and use of HIV-1 luciferase reporter viruses. 2003 , Chapter 12, Unit12.5		1
1200	Mechanisms of Retroviral Particle Maturation and Attachment. 2003 , 241-251		

1199	Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. 2003 , 101, 3416-23	59
1198	High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. 2003 , 101, 104-11	36
1197	Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. 2003 , 101, 1284-9	168
1196	Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. 2003 , 101, 1290-8	110
1195	Retroviral-mediated expression of recombinant Fancc enhances the repopulating ability of Fancc-/- hematopoietic stem cells and decreases the risk of clonal evolution. 2003 , 101, 1299-307	71
1194	Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. 2003 , 101, 4717-24	139
1193	A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. 2003 , 101, 2932-9	192
1192	Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery. 2003 , 102, 2046-52	14
1191	Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. 2003 , 102, 497-505	132
1190	IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. 2003 , 102, 4123-9	182
1189	Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. 2003 , 102, 4312-9	163
1188	Delivery of genes to the eye using lentiviral vectors. <i>Methods in Molecular Biology</i> , 2004 , 246, 439-49	1.4 4
1187	Gene-Enhanced Tissue Engineering. 2003 ,	
1186	Gene delivery to hematopoietic stem cells using lentiviral vectors. <i>Methods in Molecular Biology</i> , 2004 , 246, 429-38	1.4 39
1185	Extrinsic and intrinsic factors governing cell fate in cortical progenitor cultures. 2003 , 25, 162-72	30
1184	Tissue Engineering of Bone: The Potential Use of Gene Therapy for Difficult Bone Loss Problems. 2003 , 162-177	
1183	The history and principles of retroviral vectors. 2003 , 8, d818-35	10
1182	Lymphocytes. <i>Methods in Molecular Biology</i> , 2003 , 229, 97-105	1.4

1181	Proliferation deficiency of multipotent hematopoietic progenitors in ribosomal protein S19 (RPS19)-deficient diamond-Blackfan anemia improves following RPS19 gene transfer. 2003 , 7, 613-22	39
1180	Corneal transduction to inhibit angiogenesis and graft failure. 2003 , 44, 1837-42	53
1179	Redirecting the Tropism of HSV-1 for Gene Therapy Applications. 2003 , 377-403	
1178	HIV-2 Vectors. <i>Methods in Molecular Biology</i> , 2003 , 229, 219-31	1.4 3
1177	A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. 2003 , 8, 804	
1176	Congenital Erythropoietic Porphyria. 2003 , 43-65	7
1175	Vectors derived from the human immunodeficiency virus, HIV-1. 2003 , 8, d491-510	8
1174	Cells of respiratory epithelium. <i>Methods in Molecular Biology</i> , 2003 , 229, 287-98	1.4
1173	Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. 2003 , 7, 632-9	30
1172	Diabetes gene therapy: potential and challenges. 2003 , 3, 65-82	25
1171	Stable gene delivery to CNS cells using lentiviral vectors. <i>Methods in Molecular Biology</i> , 2004 , 246, 413-28.	4 7
1170	. 2004 ,	1
1169	Can the use of HIV-1 derived gene transfer vectors for clinical application be justified?. 2004 , 4, 65-77	5
1168	The chaperoning and assistance roles of the HIV-1 nucleocapsid protein in proviral DNA synthesis and maintenance. 2004 , 2, 79-92	29
1167	Infectious transmission and replication of human T-cell leukemia virus type 1. 2004 , 9, 2495-9	12
1166	Engineering Virus Vectors for Subunit Vaccines. 2004 , 265-287	1
1165	The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo. 2004 , 279, 36625-32	58
1164	The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. 2004 , 78, 2082-7	67

1163	Lentiviral-mediated gene transfer to model triplet repeat disorders. <i>Methods in Molecular Biology</i> , 2004 , 277, 199-213	1.4	7
1162	Using retroviruses to express genes in primary megakaryocyte lineage cells. <i>Methods in Molecular Biology</i> , 2004 , 273, 381-96	1.4	3
1161	Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75. 2004 , 279, 33421-9		82
1160	Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. 2004 , 1, 295-306		5
1159	Introduction of genes into primary murine splenic B cells using retrovirus vectors. <i>Methods in Molecular Biology</i> , 2004 , 271, 139-48	1.4	9
1158	Strategies for retargeted gene delivery using vectors derived from lentiviruses. 2004 , 4, 427-43		47
1157	In utero gene therapy: prospect and future. 2004 , 10, 3663-72		6
1156	Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. 2004 , 15, 393-404		58
1155	Genetic Modification of Neural Stem/Progenitor Cells. 2003 , 413-445		
1154	Treatment of Chronic Myeloid Leukemia Cells with Imatinib (STI571) Impairs p53 Accumulation in Response to DNA Damage. 2004 , 3, 1186-1193		22
1153	Characterization of a naphthalene derivative inhibitor of retroviral integrases. 2004 , 20, 135-44		6
1152	A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct. 2004 , 15, 865-77		14
1151	Subunit-specific coordinate upregulation of sodium pump activity in alveolar epithelial cells by lentivirus-mediated gene transfer. 2004 , 15, 457-68		5
1150	Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. 2004 , 78, 8421-36		69
1149	Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. 2004 , 78, 1219-29		117
1148	Nonrandom dimerization of murine leukemia virus genomic RNAs. 2004 , 78, 12129-39		40
1147	Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. 2004 , 117, 5591-7		37
1146	Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide. 2004 , 279, 2272-83		35

1145	Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. 2004 , 78, 8761-70	67
1144	Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. 2004 , 78, 7958-68	126
1143	PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. 2004 , 78, 912-21	123
1142	Gene silencing of HIV-1 by RNA interference. 2004 , 15, 57-65	7
1141	Influence of gag on human immunodeficiency virus type 1 species-specific tropism. 2004 , 78, 11816-22	80
1140	Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. 2004 , 2, E234	706
1139	Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. 2004 , 101, 4240-5	420
1138	Fundamental role of inferior olive connexin 36 in muscle coherence during tremor. 2004 , 101, 7164-9	64
1137	Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. 2004 , 10, 2720-4	98
1136	Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectors. 2004 , 78, 6480-8	8
1135	Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. 2004 , 279, 42072-81	79
1134	Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. 2004 , 78, 1301-13	80
1133	Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression. 2004 , 32, e106	23
1132	Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. 2004 , 78, 2327-35	95
1131	Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. 2004 , 101, 16460-5	134
1130	NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. 2004 , 101, 13618-23	132
1129	The sheep model of in utero gene therapy. 2004 , 19, 23-30	34
1128	Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes. 2004 , 78, 13072-81	31

1127	Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. 2004 , 78, 1421-30	51
1126	Transduction of terminally differentiated neurons by avian sarcoma virus. 2004 , 78, 4902-6	19
1125	Identification of cyclin D3 as a direct target of E2A using DamID. 2004 , 24, 8790-802	27
1124	Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. 2004 , 101, 16909-14	80
1123	Gene transfer in tissue repair: status, challenges and future directions. 2004 , 4, 1373-86	33
1122	Jaagsiekte sheep retrovirus envelope efficiently pseudotypes human immunodeficiency virus type 1-based lentiviral vectors. 2004 , 78, 2642-7	22
1121	Clonal selection for transcriptionally active viral oncogenes during progression to cancer. 2004 , 78, 11172-86	106
1120	Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. 2004 , 25, 1753	1
1119	Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy. 2004 , 13, 705	2
1118	Adeno-associated virus and lentivirus pseudotypes for lung-directed gene therapy. 2004 , 1, 309-14	14
1117	Ca(2+)-induced recruitment of the secretory vesicle protein DOC2B to the target membrane. 2004 , 279, 23740-7	37
1116	Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdala-dependent fear conditioning. 2004 , 24, 4796-806	298
1115	A lentiviral cDNA library employing lambda recombination used to clone an inhibitor of human immunodeficiency virus type 1-induced cell death. 2004 , 78, 11352-9	25
1114	Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. 2004 , 78, 5670-8	248
1113	Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1. 2004 , 279, 13659-67	116
1112	Trim5alpha protein restricts both HIV-1 and murine leukemia virus. 2004 , 101, 10786-91	381
1111	A functional role of postsynaptic density-95-guanylate kinase-associated protein complex in regulating Shank assembly and stability to synapses. 2004 , 24, 9391-404	73
1110	LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. 2004 , 101, 16531-6	64

1109	Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. 2004 , 10, 545-52	58
1108	Generation of transgenic cattle by lentiviral gene transfer into oocytes. 2004 , 71, 405-9	125
1107	Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. 2004 , 9, 76-84	26
1106	Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. 2004 , 9, 85-92	22
1105	Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. 2004 , 9, 557-65	3
1104	Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. 2004 , 10, 45-56	32
1103	Lentivectors for regulated and reversible cutaneous gene delivery. 2004 , 9, 93-100	31
1102	Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. 2004 , 9, 209-17	129
1101	Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. 2004 , 15, 562-73	28
1100	Trinucleotide Repeat Protocols. 2004 ,	3
1099	Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. 2004 , 13, 1803-13	82
1098	Current status of catheter- and stent-based gene therapy. 2004 , 64, 208-16	49
1097	Identification of iduronate-2-sulfatase in mouse pancreatic islets. 2004 , 287, E983-90	6
1096	Regulation of p53 stability and function in HCT116 colon cancer cells. 2004 , 279, 7598-605	85
1095	Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. 2004 , 78, 11980-7	111
1094	Somatic cell engineering and the immunotherapy of leukemias and lymphomas. 2004 , 51, 347-70	3
1093	Histopathological and cognitive defects induced by Nef in the brain. 2004 , 18, 1851-61	34
1092	Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release. 2004 , 78, 6636-48	70

1091	Therapeutic strategies for Duchenne and Becker dystrophies. 2004 , 240, 1-30	24
1090	Factors influencing the titer and infectivity of lentiviral vectors. 2004 , 15, 976-88	88
1089	Frequent dual initiation in human immunodeficiency virus-based vectors containing two primer-binding sites: a quantitative in vivo assay for function of initiation complexes. 2004 , 78, 5402-13	10
1088	Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway. 2004 , 78, 8573-81	81
1087	CD81-induced behavioural changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. 2004 , 19, 1621-33	47
1086	In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration. 2004 , 20, 3473-88	41
1085	Frame-shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid beta40. 2004 , 90, 712-23	11
1084	Targeting platelet GPIIb/IIIa transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIIb/IIIa and GPIIb/IIIa. 2004 , 2, 1989-97	30
1083	Multiple facets of macrophages in renal injury. 2004 , 66, 542-57	110
1082	Lentivirus-mediated gene transfer to human epidermis. 2004 , 9, 269-75	20
1081	Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. 2004 , 10, 835-41	68
1080	HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. 2004 , 10, 197-201	144
1079	Clinical strategies for expansion of haematopoietic stem cells. 2004 , 4, 878-88	126
1078	Suppression of retroviral infection by the RAD52 DNA repair protein. <i>EMBO Journal</i> , 2004 , 23, 3421-9	13 58
1077	Efficient production of germline transgenic chickens using lentiviral vectors. 2004 , 5, 728-33	296
1076	SDF-1alpha/CXCL12 enhances retroviral-mediated gene transfer into immature subsets of human and murine hematopoietic progenitor cells. 2004 , 11, 61-9	5
1075	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. 2004 , 11, 85-93	32
1074	Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy. 2004 , 11, 253-9	18

1073	Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. 2004 , 11, 591-8	58
1072	Sea urchin insulator protects lentiviral vector from silencing by maintaining active chromatin structure. 2004 , 11, 819-28	43
1071	Green fluorescent protein: green cells do not always indicate gene expression. 2004 , 11, 882-3	26
1070	Efficient lentiviral transduction of Herpesvirus saimiri immortalized T cells as a model for gene therapy in primary immunodeficiencies. 2004 , 11, 956-61	25
1069	Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. 2004 , 11, 1627-37	32
1068	Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis. 2004 , 11 Suppl 1, S67-75	45
1067	Response to Whitelaw: Lentiviral transgenesis in livestock. 2004 , 22, 159-160	4
1066	Detection and quantitation of human immunodeficiency virus type-1 particles by confocal microscopy. 2004 , 120, 13-21	7
1065	Tip, an Lck-interacting protein of Herpesvirus saimiri, causes Fas- and Lck-dependent apoptosis of T lymphocytes. 2004 , 320, 313-29	21
1064	Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. 2004 , 325, 413-24	30
1063	Endogenously expressed HIV-1 nef down-regulates antigen-presenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. 2004 , 326, 79-89	44
1062	Determinants of interferon-stimulated gene induction by RNAi vectors. 2004 , 72, 103-11	145
1061	In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors. 2004 , 5, 18	13
1060	Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. 2004 , 5, 4	81
1059	ARF1 regulates Nef-induced CD4 degradation. 2004 , 14, 1056-64	43
1058	Gene therapy for genetic diseases: On the horizon. 2004 , 4, 411-422	10
1057	Synergies of microtissue design, viral transduction and adjustable transgene expression for regenerative medicine. 2004 , 39, 3-16	11
1056	Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. 2004 , 101, 18206-11	391

1055	Lentiviral gp34/OX40L gene transfer into dendritic cells facilitates alloreactive CD4+ T-cell response in vitro. 2004 , 79, 377-83	8
1054	Transduction patterns of pseudotyped lentiviral vectors in the nervous system. 2004 , 9, 101-11	123
1053	Nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases. Approaches and perspectives. 2004 , 93, 171-93	4
1052	Lentiviral vectors. 2004 , 11, 439-49	45
1051	Lentiviral transgenesis. 2004 , 13, 513-22	86
1050	Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes. 2004 , 47, 686-94	55
1049	Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. 2004 , 59, 370-82	22
1048	Toward construction of a self-sustained clock-like expression system based on the mammalian circadian clock. 2004 , 87, 234-42	15
1047	Aberrant expression of alpha-Gal on primary human endothelium does not confer susceptibility to NK cell cytotoxicity or increased NK cell adhesion. 2004 , 34, 1185-95	26
1046	Lentivirally generated eGFP-transgenic rats allow efficient cell tracking in vivo. 2004 , 39, 94-9	68
1045	Strategies for cancer gene therapy. 2004 , 85, 28-35	33
1044	Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation. 2004 , 6, 147-54	16
1043	Surface-engineering of lentiviral vectors. 2004 , 6 Suppl 1, S83-94	47
1042	Toolbox for retrovectorologists. 2004 , 6 Suppl 1, S67-82	45
1041	FIV: from lentivirus to lentivector. 2004 , 6 Suppl 1, S95-104	38
1040	Lentiviral vectors: optimization of packaging, transduction and gene expression. 2004 , 6 Suppl 1, S125-38	92
1039	Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. 2004 , 6, 249-59	36
1038	Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication. 2004 , 6, 268-77	1

1037	Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors. 2004 , 6, 1014-22	14
1036	Hepatocyte-specific gene expression from integrated lentiviral vectors. 2004 , 6, 974-83	20
1035	Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. 2004 , 6, 963-73	65
1034	Lentiviral vectors for treating and modeling human CNS disorders. 2004 , 6, 951-62	61
1033	Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. 2004 , 6, 1049-60	22
1032	Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. 2004 , 6, 1197-205	18
1031	Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. 2004 , 6, 76-85	67
1030	Role of Nup98 in nuclear entry of human immunodeficiency virus type 1 cDNA. 2004 , 6, 715-24	49
1029	Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. <i>Cancer Research</i> , 2004 , 64, 4833-40	10.1 165
1028	Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. 2004 , 146, 451-76	97
1027	Maintenance of pluripotency in human embryonic stem cells stably over-expressing enhanced green fluorescent protein. 2004 , 13, 636-45	50
1026	Use of DNA microarrays to monitor host response to virus and virus-derived gene therapy vectors. 2004 , 4, 345-56	19
1025	Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. 2004 , 78, 4029-36	68
1024	Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. 2004 , 15, 221-6	55
1023	Platelets and Megakaryocytes. 2004 ,	4
1022	Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. 2004 , 15, 1091-100	54
1021	Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. 2004 , 104, 2523-31	108
1020	The chaperoning and assistance roles of the HIV-1 nucleocapsid protein in proviral DNA synthesis and maintenance. 2004 , 36, 1668-1668	

1019	Stem cell gene transfer--efficacy and safety in large animal studies. 2004 , 10, 417-31	24
1018	Role of Nup98 in nuclear entry of human immunodeficiency virus type 1BcDNA. 2004 , 6, 715-715	
1017	Gene therapy of liver diseases. 2004 , 4, 1073-91	28
1016	Introduction to Retroviruses. 2004 , 57-93	
1015	RNAi in Mammals. 2004 , 101-246	
1014	Prospects for transgenesis in the chick. 2004 , 121, 1179-86	72
1013	Novel integrase-defective lentiviral episomal vectors for gene transfer. 2004 , 15, 361-72	116
1012	B Cell Protocols. 2004 ,	4
1011	Signal transduction pathways in Bcr-Abl transformed cells. 2004 , 119, 239-70	14
1010	Transduction of human islets with pseudotyped lentiviral vectors. 2004 , 15, 211-9	37
1009	Transactivator and structurally optimized inducible lentiviral vectors. 2004 , 10, 585-96	29
1008	Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis. 2004 , 15, 588-96	20
1007	The chaperoning and assistance roles of the HIV-1 nucleocapsid protein in proviral DNA synthesis and maintenance. 2004 , 36, 1668-86	42
1006	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. <i>Experimental Neurology</i> , 2004 , 185, 26-35	5:7 48
1005	Ini1/hSNF5 is dispensable for retrovirus-induced cytoplasmic accumulation of PML and does not interfere with integration. 2004 , 578, 291-6	13
1004	Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease. 2004 , 318, 381-90	21
1003	Efficient in vitro transduction of naive murine B cells with lentiviral vectors. 2004 , 318, 673-9	5
1002	Prolonged liver-specific transgene expression by a non-primate lentiviral vector. 2004 , 320, 998-1006	32

1001	Mutational analysis of the predicted secondary RNA structure of the Mason-Pfizer monkey virus packaging signal. 2004 , 99, 35-46	8
1000	Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. 2004 , 13, 191-200	24
999	Transgene expression of alpha(1,2)-fucosyltransferase-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis a or binding to P-selectin. 2004 , 164, 371-83	50
998	Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice. 2004 , 16, 139-49	44
997	A preproenkephalin-neurofilament chimeric promoter in a helper virus-free herpes simplex virus vector enhances long-term expression in the rat striatum. 2004 , 16, 596-603	12
996	How to keep injured CNS neurons viable--strategies for neuroprotection and gene transfer to retinal ganglion cells. 2004 , 26, 1-16	9
995	Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. 2004 , 40, 291-7	30
994	In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. 2004 , 341, 635-49	47
993	Anti-termination by SIV Tat requires flexibility of the nascent TAR structure. 2004 , 344, 11-28	9
992	RNA interfering approach for clarifying the PPARgamma pathway using lentiviral vector expressing short hairpin RNA. 2004 , 560, 178-82	42
991	Genetic control of retrovirus susceptibility in mammalian cells. 2004 , 38, 61-85	72
990	An improved beta-galactosidase reporter gene. 2004 , 108, 17-30	17
989	Gene therapy of the corneal epithelium. 2004 , 44, 81-90	12
988	Neuroprotection in a rat Parkinson model by GDNF gene therapy using ElAV vector. 2004 , 15, 985-90	46
987	Highly efficient lentiviral-mediated human cytokine transgenesis on the NOD/scid background. 2004 , 103, 580-2	14
986	Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. 2004 , 103, 3710-6	69
985	Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. 2004 , 103, 2942-9	201
984	Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. 2004 , 103, 4062-9	141

983	Lentiviral vector for hemophilia gene therapy. 2004 , 103, 3609-3610	
982	Retroviral transduction in fetal thymic organ culture. 2005 , 105, 311-22	6
981	Lentiviral vectors. 2005 , 99, 169-91	19
980	Lentiviral vectors for the treatment of Wiskott-Aldrich syndrome. 2005 , 12, 555-6	
979	A simple and highly effective method for the stable transduction of uncultured porcine hepatocytes using lentiviral vector. 2005 , 14, 489-96	23
978	Long-term transgene expression and survival of transgene-expressing grafts following lentivirus transduction of bone marrow side population cells. 2005 , 79, 882-8	2
977	Tolerance by selective in vivo expansion of foreign major histocompatibility complex-transduced autologous bone marrow. 2005 , 80, 362-9	2
976	Efficient gene transfer to retinal pigment epithelium cells with long-term expression. 2005 , 25, 193-201	34
975	Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. 2005 , 105, 2802-11	38
974	Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. 2005 , 105, 2699-706	66
973	Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. 2005 , 105, 3824-32	116
972	Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. 2005 , 106, 1048-53	53
971	Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. 2005 , 106, 1552-8	64
970	Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. 2005 , 106, 3386-95	39
969	In vivo gene transfer into rat bone marrow progenitor cells using rSV40 viral vectors. 2005 , 106, 2655-62	14
968	Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. 2005 , 105, 2510-8	146
967	Advanced targeting strategies for murine retroviral and adeno-associated viral vectors. 2005 , 99, 147-67	9
966	Relative activity of the feline immunodeficiency virus promoter in feline and primate cell lines. 2005 , 7, 233-9	17

965	HIV-1-derived self-inactivating lentivirus vector induces megakaryocyte lineage-specific gene expression. 2005 , 7, 240-7	9
964	Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. 2005 , 7, 426-36	50
963	Critical role of beta3 integrin in experimental postmenopausal osteoporosis. 2005 , 20, 2116-23	46
962	A new versatile and compact lentiviral vector. 2005 , 29, 47-56	13
961	Human fetal mesenchymal stem cells as vehicles for gene delivery. 2005 , 23, 93-102	160
960	In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. 2005 , 92, 1243-55	53
959	Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. 2005 , 12, 346-56	13
958	No role of alpha-Gal in human monocyte-endothelial cell interactions in vitro. 2005 , 62, 445-52	3
957	Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. 2005 , 7, 493-500	122
956	Endosome-to-cytosol transport of viral nucleocapsids. 2005 , 7, 653-64	253
955	Quantitative analysis of gene expression in living adult neural stem cells by gene trapping. 2005 , 2, 363-70	21
954	Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. 2005 , 8, 1343-9	344
953	Supernatural T cells: genetic modification of T cells for cancer therapy. 2005 , 5, 928-40	129
952	Genome-wide analysis of retroviral DNA integration. 2005 , 3, 848-58	335
951	Retroviral DNA integration and the DNA damage response. 2005 , 12 Suppl 1, 971-8	98
950	Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer. 2005 , 12, 22-9	15
949	Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR. 2005 , 24, 1914-23	27
948	Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. 2005 , 436, 103-7	491

947	DermaVir: a novel topical vaccine for HIV/AIDS. 2005 , 124, 160-9	75
946	Role of injured endothelial cells in the recruitment of human pulp cells. 2005 , 50, 109-13	30
945	Long-term persistence of a nonintegrated lentiviral vector in mouse hematopoietic stem cells. 2005 , 33, 873-82	18
944	[Gene therapy: a reality for tomorrow?]. 2005 , 29, 724-31	2
943	A new cell-based assay for measuring the forward mutation rate of HIV-1. 2005 , 124, 95-104	22
942	Harnessing HIV for therapy, basic research and biotechnology. 2005 , 23, 42-7	100
941	Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts. 2005 , 20, 583-93	25
940	Gene therapy in the cornea. 2005 , 24, 537-59	78
939	Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potentially protects human hematopoietic cells from HIV-1 infection. 2005 , 332, 258-71	6
938	Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. 2005 , 332, 418-29	24
937	A nuclear localization signal in the matrix of spleen necrosis virus (SNV) does not allow efficient gene transfer into quiescent cells with SNV-derived vectors. 2005 , 338, 292-6	10
936	Effects of cell cycle status on early events in retroviral replication. 2005 , 94, 880-9	41
935	Characterization of five evolutionary conserved regions of the human tyrosine hydroxylase (TH) promoter: implications for the engineering of a human TH minimal promoter assembled in a self-inactivating lentiviral vector system. 2005 , 204, 666-77	24
934	Transferrin receptor co-localizes and interacts with the hemochromatosis factor (HFE) and the divalent metal transporter-1 (DMT1) in trophoblast cells. 2005 , 204, 901-12	23
933	Lentiviral transduction of microglial cells. 2005 , 50, 48-55	28
932	Different mechanisms preclude mutant CLDN14 proteins from forming tight junctions in vitro. 2005 , 25, 543-9	40
931	Gene delivery to embryonic stem cells. 2005 , 75, 10-8	45
930	Somatic transgenesis in the avian model system. 2005 , 75, 19-27	13

929	Viral vectors as tools to model and treat neurodegenerative disorders. 2005 , 7, 530-9	42
928	VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVtk-GFP triple fusion construct. 2005 , 7, 898-907	17
927	Assessment of optimal transduction of primary human skin keratinocytes by viral vectors. 2005 , 7, 1178-86	24
926	Upscaling of lentiviral vector production by tangential flow filtration. 2005 , 7, 1299-310	130
925	Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production. 2005 , 7, 1390-9	40
924	Sustained elevation of neutrophils in rats induced by lentivirus-mediated G-CSF delivery. 2005 , 7, 1510-6	3
923	Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. 2005 , 25, 522-9	20
922	[Comparison of several viral vectors for gene therapy of corneal endothelial cells]. 2005 , 102, 1168-74	3
921	Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling. 2005 , 273, 184-96	40
920	Methods in clonal analysis and applications. 2005 , 45, 321-39	22
919	Cellular and Gene Therapy Approaches to Spinal Cord Injury. 2005 , 18, 65-103	0
918	Gene Therapy for Parkinson's Disease. 2005 , 18, 213-245	
917	Gene therapy. 2005 , 329-346	
916	siRNA delivery by lentiviral vectors: Design and applications. 2005 , 174-185	
915	Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. 2005 , 11, 411-6	123
914	Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. 2005 , 79, 1765-71	34
913	Altering the tropism of lentiviral vectors through pseudotyping. 2005 , 5, 387-98	388
912	SIRT1 regulates HIV transcription via Tat deacetylation. 2005 , 3, e41	249

911	Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. 2005 , 5, 375-85	58
910	Retrovirus silencing and vector design: relevance to normal and cancer stem cells?. 2005 , 5, 367-73	54
909	Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. 2005 , 3, 157-81	17
908	Editorial [Hot Topic: Recombinant Adeno-Associated Virus: Current Achievements and Limitations (Guest Editor: Philippe Moullier)]. 2005 , 5, 263-263	
907	Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome. 2005 , 79, 12035-44	73
906	Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. 2005 , 79, 834-40	19
905	Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells. 2005 , 79, 13190-4	35
904	Ubiquitous GFP expression in transgenic chickens using a lentiviral vector. 2005 , 132, 935-40	93
903	Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. 2005 , 79, 8410-21	48
902	Protein kinase X activates ureteric bud branching morphogenesis in developing mouse metanephric kidney. 2005 , 16, 3543-52	19
901	Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. 2005 , 86, 765-771	26
900	Genetic recombination of human immunodeficiency virus type 1 in one round of viral replication: effects of genetic distance, target cells, accessory genes, and lack of high negative interference in crossover events. 2005 , 79, 1666-77	81
899	In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. 2005 , 12, 988-98	14
898	Newborn liver gene transfer by an HIV-2-based lentiviral vector. 2005 , 12, 803-14	11
897	HIV-1-derived lentiviral vectors and fetal route of administration on transgene biodistribution and expression in rhesus monkeys. 2005 , 12, 821-30	38
896	HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. 2005 , 18, 190-6	61
895	Gene therapy of storage disorders by retroviral and lentiviral vectors. 2005 , 16, 1133-42	37
894	Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. 2005 , 16, 741-51	118

893	Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. 2005 , 16, 1227-36	29
892	Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. 2005 , 4, 1247-53	42
891	Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. 2005 , 12, 1242-52	58
890	Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. 2005 , 11, 452-9	41
889	Prolonged transgene expression in murine salivary glands following non-primate lentiviral vector transduction. 2005 , 12, 137-43	14
888	Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (<i>Macaca mulatta</i>): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. 2005 , 12, 87-98	60
887	Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein. 2005 , 11, 645-51	25
886	Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes. 2005 , 11, 26-34	37
885	Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. 2005 , 12, 900-9	217
884	Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. 2005 , 11, 932-40	124
883	Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. 2005 , 11, 390-8	119
882	Stable transduction of primary human monocytes by simian lentiviral vector PBj. 2005 , 12, 1206-16	23
881	Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. 2005 , 11, 470-82	16
880	Current status of gene therapy strategies to treat HIV/AIDS. 2005 , 11, 823-42	81
879	Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. 2005 , 12, 669-79	50
878	A novel role for GADD45beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. 2005 , 280, 38544-55	81
877	Phosphoinositide binding by the disabled-1 PTB domain is necessary for membrane localization and Reelin signal transduction. 2005 , 280, 9671-7	30
876	Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. 2005 , 175, 6402-11	43

875	Monosynaptic pathway from rat vibrissa motor cortex to facial motor neurons revealed by lentivirus-based axonal tracing. 2005 , 25, 8250-8	100
874	Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. <i>Cancer Research</i> , 2005 , 65, 2532-6	10.1 178
873	HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis. 2005 , 102, 11017-22	75
872	Human immunodeficiency virus type 1 latency model for high-throughput screening. 2005 , 49, 5185-8	20
871	Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. 2005 , 19, 1752-4	11
870	Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. 2005 , 79, 4257-69	56
869	DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. 2005 , 79, 2973-8	99
868	In vivo imaging of engrafted neural stem cells: its application in evaluating the optimal timing of transplantation for spinal cord injury. 2005 , 19, 1839-41	200
867	Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. 2005 , 174, 758-66	17
866	Neuroacanthocytosis Syndromes. 2005 ,	4
865	Versatility of gene therapy vectors through viruses. 2005 , 5, 639-62	17
864	Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. 2005 , 79, 2528-40	129
863	Reduced mobilization of Rev-responsive element-deficient lentiviral vectors. 2005 , 79, 9359-62	18
862	The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. 2005 , 79, 1389-96	40
861	Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells. 2005 , 79, 2058-65	32
860	Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. 2005 , 25, 5774-83	98
859	Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation. 2005 , 16, 1777-87	48
858	Overexpression of fasciculation and elongation protein zeta-1 (FEZ1) induces a post-entry block to retroviruses in cultured cells. 2005 , 19, 1105-15	29

857	Collagen alpha1(I) gene (COL1A1) is repressed by RFX family. 2005 , 280, 21004-14	52
856	Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells. 2005 , 27, 820-6	6
855	Gene Therapy for beta-thalassemia. 2005 , 2005, 45-50	17
854	Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. 2005 , 33, 1913-23	152
853	El futuro en la infecci3n por VIH: terapia g3nica y ARN de interferencia. 2005 , 23, 68-75	
852	The future of HIV infection: gene therapy and RNA interference. 2005 , 23, 76-83	2
851	Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies. 2005 , 16, 223-34	29
850	Gene therapy: twenty-first century medicine. 2005 , 74, 711-38	475
849	The application of tissue engineering to regeneration of pulp and dentin in endodontics. 2005 , 31, 711-8	271
848	Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors. 2005 , 16, 49-56	34
847	Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. 2005 , 79, 6610-9	224
846	Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. 2005 , 280, 23709-17	115
845	Regulatable gene expression systems for gene therapy applications: progress and future challenges. 2005 , 12, 189-211	217
844	A lentiviral expression system demonstrates that L* protein of Theiler's murine encephalomyelitis virus (TMEV) has an anti-apoptotic effect in a macrophage cell line. 2005 , 38, 201-7	10
843	Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons. 2005 , 135, 48-57	11
842	hCMV and Tet promoters for inducible gene expression in rat neurons in vitro and in vivo. 2005 , 19, 283-92	17
841	HIV-based vectors and angiogenesis following rabbit hindlimb ischemia. 2005 , 123, 55-66	10
840	Changes in integrin expression during adipocyte differentiation. 2005 , 2, 165-77	141

839	Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. 2005 , 31, 368-74		10
838	Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. 2005 , 80, 787-94		39
837	Loss of gene expression in lentivirus- and retrovirus-transduced neural progenitor cells is correlated to migration and differentiation in the adult spinal cord. <i>Experimental Neurology</i> , 2005 , 195, 127-39	5.7	45
836	Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. 2005 , 167, 609-18		270
835	A lentiviral expression system demonstrates that L* protein of Theiler's murine encephalomyelitis virus (TMEV) is essential for virus growth in a murine macrophage-like cell line. 2005 , 108, 23-8		15
834	Disruption of polycystin-1 function interferes with branching morphogenesis of the ureteric bud in developing mouse kidneys. 2005 , 286, 16-30		27
833	Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo. 2005 , 38, 333-44		29
832	Use of recombinant adeno-associated viral vectors as a tool for labeling bone marrow cells. 2005 , 38, 799-802		6
831	Embryonic stem cells: prospects for developmental biology and cell therapy. 2005 , 85, 635-78		583
830	Identification of unique reciprocal and non reciprocal cross packaging relationships between HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral vector system with highly favourable features for in vivo testing and clinical usage. 2005 , 2, 55		23
829	Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein. 2005 , 2, 71		6
828	Real-time quantitative PCR for the design of lentiviral vector analytical assays. 2005 , 12 Suppl 1, S36-50		32
827	Brain-derived neurotrophic factor in amygdala-dependent learning. 2005 , 11, 323-33		110
826	Hematopoietic stem cell transduction and amplification in large animal models. 2005 , 16, 1355-66		29
825	Atherosclerosis: Diet and Drugs. 2005 ,		2
824	Retro/lentiviral vectors. 2005 ,		
823	Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. 2005 , 25, 11748-56		26
822	Silencing and variegation of gammaretrovirus and lentivirus vectors. 2005 , 16, 1241-6		279

821	The effects of N-terminal insertion into VSV-G of an scFv peptide. 2006 , 3, 69	13
820	Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. 2006 , 17, 577-88	23
819	RNA Towards Medicine. 2006 ,	
818	The application of siRNA technology to cancer biology discovery. 2007 , 96, 75-102	25
817	Retrovirus vectors: toward the plentivirus?. 2006 , 13, 1050-63	72
816	Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. 2006 , 13, 382-90	68
815	Gene delivery to the retina using lentiviral vectors. 2006 , 572, 255-66	17
814	Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. 2006 , 19, 690-701	34
813	Production and titration of lentiviral vectors. 2006 , Chapter 4, Unit 4.21	73
812	Endogenous Wnt signaling promotes proliferation and suppresses osteogenic differentiation in human adipose derived stromal cells. 2006 , 12, 111-21	90
811	Human Embryonic Stem Cell Protocols. 2006 ,	1
810	Lentiviral vectors mediate efficient and stable gene transfer in adult neural stem cells in vivo. 2006 , 17, 635-50	72
809	Construction and use of retroviral vectors encoding the toxic gene barnase. 2006 , 14, 555-63	24
808	Retinal Degenerative Diseases. 2006 ,	5
807	Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. <i>Cancer Research</i> , 2006 , 66, 5763-71	10.1 41
806	Therapeutic strategies for the inherited neuropathies. 2006 , 8, 255-78	24
805	The Ferrier Lecture 1998. The molecular biology of consciousness investigated with genetically modified mice. 2006 , 361, 2239-59	20
804	Functional lentiviral vectors for xeroderma pigmentosum gene therapy. 2006 , 126, 424-30	17

803	Gene therapy: future or flop. 2006 , 53, 621-38	6
802	Generation of H9 T-cells stably expressing a membrane-bound form of the cytoplasmic tail of the Env-glycoprotein: lack of transcomplementation of defective HIV-1 virions encoding C-terminally truncated Env. 2006 , 3, 27	2
801	Wild-type and central DNA flap defective HIV-1 lentiviral vector genomes: intracellular visualization at ultrastructural resolution levels. 2006 , 3, 38	26
800	The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. 2006 , 3, 47	40
799	Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination. 2006 , 3, 91	26
798	Cerebellar neurons and glial cells are transducible by lentiviral vectors without decrease of cerebellar functions. 2006 , 28, 216-21	19
797	Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. 2006 , 13, 814-22	40
796	A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. 2006 , 14, 276-84	46
795	Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats: an animal model for Wilson disease. 2006 , 41, 974-82	42
794	Postnatal skeletal stem cells. 2006 , 419, 117-48	128
793	Targeting vascular injury using Hantavirus-pseudotyped lentiviral vectors. 2006 , 13, 694-704	32
792	Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells. 2006 , 580, 3775-8	19
791	A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. <i>Cell</i> , 2006 , 124, 1283-98	56.2 1340
790	Capacity of human beta-defensin expression in gene-transduced and cytokine-induced cells. 2006 , 339, 344-54	5
789	Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA. 2006 , 344, 478-83	15
788	A lentiviral vector with expression controlled by E2F-1: a potential tool for the study and treatment of proliferative diseases. 2006 , 348, 1411-8	10
787	From leading role to the backstage: mesenchymal stem cells as packaging cell lines for in situ production of viral vectors. 2006 , 67, 922-5	3
786	Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors. 2006 , 50, 911-21	237

785	Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: Averting cytotoxicity by alloreactive T lymphocytes. 2006 , 38, 3184-8	23
784	New Technologies in Cardiovascular Research: Gene Therapy. 2006 , 85-101	
783	Beyond retrovirus infection: HIV meets gene therapy. 2006 , 29, 367-379	3
782	Gene Therapy for Spinal Cord Injury. 2006 , 273-288	2
781	Vectors and Gene Therapy. 2006 ,	
780	Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. 2006 , 70, 1503-8	31
779	Neuropeptide gene therapy for epilepsy: viral vectors, stem cells and neurogenesis. 2006 , 1, 843-851	2
778	Intestinal Stem Cells and the Development of Colorectal Neoplasia. 2006 , 245-286	
777	Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. 2006 , 110, 37-46	25
776	KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2. 2006 , 107, 277-84	41
775	Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. 2006 , 290, L492-500	14
774	Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. 2006 , 82, 794-803	27
773	Comparison of lentiviral vector titration methods. 2006 , 6, 34	107
772	Gene-enhanced tissue engineering for dental hard tissue regeneration: (1) overview and practical considerations. 2006 , 2, 12	15
771	Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells. 2006 , 33, 1196-201	6
770	Long-term gene expression and metabolic control exerted by lentivirus-transduced pancreatic islets. 2006 , 13, 195-203	16
769	Transplantation of human CD34+ stem cells from umbilical cord blood to rats with thioacetamide-induced liver cirrhosis. 2006 , 13, 529-35	23
768	Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. 2003 , 13, 364-72	93

767	Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta. 2006 , 96, 1572-9	7
766	Defective axonal transport of neurofilament proteins in neurons overexpressing peripherin. 2006 , 98, 926-38	48
765	Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion. 2006 , 98, 1619-31	14
764	Gene therapy for pediatric AIDS. 2000 , 918, 318-29	14
763	RD114-Pseudotyped Oncoretroviral Vectors. 2006 , 938, 262-277	30
762	Engineering tolerance into transplanted beta cell lines. 2001 , 944, 267-70	2
761	A phenotypic recessive, post-entry block in rabbit cells that results in aberrant trafficking of HIV-1. 2006 , 7, 978-92	14
760	Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. 2006 , 24, 687-96	556
759	Effective gene therapy with nonintegrating lentiviral vectors. 2006 , 12, 348-53	368
758	The double life of lentiviruses. 2006 , 3, 69	1
757	Microarrays of lentiviruses for gene function screens in immortalized and primary cells. 2006 , 3, 117-22	115
756	Tuning silence: conditional systems for RNA interference. 2006 , 3, 682-8	112
755	Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. 2006 , 3, 817-24	226
754	Design and cloning of lentiviral vectors expressing small interfering RNAs. 2006 , 1, 234-40	77
753	Production and purification of lentiviral vectors. 2006 , 1, 241-5	710
752	Rapid generation of knockdown transgenic mice by silencing lentiviral vectors. 2006 , 1, 286-92	25
751	Ten years of Nature Biotechnology research. 2006 , 24, 301-8	4
750	The delivery problem. 2006 , 24, 305-306	1

749	Silence is golden. 2006 , 24, 306-308	2
748	Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. 2006 , 13, 32-43	27
747	Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context. 2006 , 13, 919-29	7
746	Activation of the anaphase promoting complex by HTLV-1 tax leads to senescence. <i>EMBO Journal</i> , 2006 , 25, 1741-52	13 80
745	Interaction of Moloney murine leukemia virus matrix protein with IQGAP. <i>EMBO Journal</i> , 2006 , 25, 2155-66	44
744	Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. 2006 , 13, 715-24	71
743	Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. 2006 , 13, 1068-79	86
742	With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). 2006 , 13, 991-4	128
741	T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. 2006 , 13, 1480-92	67
740	Local gene transfer to calcified tissue cells using prolonged infusion of a lentiviral vector. 2006 , 13, 1595-602	18
739	Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. 2006 , 25, 4483-90	11
738	Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. 2006 , 25, 4429-40	84
737	Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. 2006 , 25, 5969-84	132
736	Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. 2006 , 106, 126-34	38
735	Gene delivery into primary cerebral cortical neurons by lentiviral vector. 2006 , 30, 777-83	6
734	Both the 5' and 3' LTRs of FIV contain minor RNA encapsidation determinants compared to the two core packaging determinants within the 5' untranslated region and gag. 2006 , 8, 767-78	17
733	Lentiviral vectors for use in the central nervous system. 2006 , 13, 484-93	100
732	Promoter dependence of transgene expression by lentivirus-transduced human blood-derived endothelial progenitor cells. 2006 , 24, 199-208	22

731	High yield of cells committed to the photoreceptor fate from expanded mouse retinal stem cells. 2006 , 24, 2060-70	38
730	Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors. 2006 , 30, 105-6	9
729	Evaluation of laser-assisted lentiviral transgenesis in bovine. 2006 , 15, 447-54	13
728	A role for atm in E-cadherin-mediated contact inhibition in epithelial cells. 2006 , 99, 143-53	8
727	Reverse genetics for proteomics: from proteomic discovery to scientific content. 2006 , 113, 1033-40	3
726	Persistent inhibition of FLIP(L) expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells. 2006 , 11, 255-63	25
725	Structural genomics for membrane proteins. 2006 , 63, 2597-607	55
724	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. 2021 , 29, 23-31.e4	198
723	Nanoparticle-mediated therapy of neuronal damage in the neonatal brain. 2021 , 61, 102208	
722	In vivo cell tracking with viral vector mediated genetic labeling. 2021 , 350, 109021	0
721	Gene therapy using haematopoietic stem and progenitor cells. 2021 , 22, 216-234	39
720	Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 20, 95-108	6.4 4
719	Merits of the 'good' viruses: the potential of virus-based therapeutics. 2021 , 21, 731-740	3
718	Advances in Lentivirus Purification. 2021 , 16, e2000019	10
717	Illuminating the Regenerative Properties of Stem Cells In Vivo with Bioluminescence Imaging. 2021 , 16, e2000248	0
716	Curative gene therapies for rare diseases. 2021 , 12, 267-276	4
715	Gene and cell therapy. 2021 , 463-488	
714	Recent approaches to target apoptosis in neurological disorders. 2021 , 217-283	1

713	Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology. 2020 , 11, 611163	19
712	SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses.	1
711	High-Level Production of Recombinant Eukaryotic Proteins from Mammalian Cells Using Lentivirus. <i>Methods in Molecular Biology</i> , 2021 , 2305, 83-104	1.4 0
710	Delivery Methods, Resources and Design Tools in CRISPR/Cas. 2021 , 63-116	3
709	HIV modifies the m6A and m5C epitranscriptomic landscape of the host cell.	0
708	Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. 2021 , 17, e1009246	135
707	Targeted Gene Delivery: Where to Land. 2020 , 2, 609650	3
706	A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies. 2020 , 2, 617780	1
705	Nonviral gene delivery to T cells with Lipofectamine LTX. 2021 , 118, 1693-1706	2
704	Supramolecular Peptide Nanofibrils with Optimized Sequences and Molecular Structures for Efficient Retroviral Transduction. 2021 , 31, 2009382	4
703	Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging. 2021 , 327, 18-27	3
702	Viral vector platforms within the gene therapy landscape. 2021 , 6, 53	104
701	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. 2021 , 13,	7
700	A lysine ring in HIV capsid pores coordinates IP6 to drive mature capsid assembly. 2021 , 17, e1009164	7
699	Cofilin pathology is a new player on β -synuclein-induced spine impairment in models of hippocampal synucleinopathy.	1
698	Novel targeted therapies for Parkinson's disease. 2021 , 27, 17	13
697	Lentiviral Vector Bioprocessing. 2021 , 13,	18
696	Production of Class II MHC Proteins in Lentiviral Vector-Transduced HEK-293T Cells for Tetramer Staining Reagents. 2021 , 1, e36	0

695	A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. 2021 , 131,	11
694	Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies. 2021 , 12, 639475	5
693	CAR T-Cell Production Using Nonviral Approaches. 2021 , 2021, 6644685	4
692	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. 2021 , 16, e0248348	41
691	A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. 2021 , 54, 542-556.e9	35
690	A stable immature lattice packages IP for HIV capsid maturation. 2021 , 7,	9
689	Quantitative analysis of dense-core vesicle fusion in rodent CNS neurons. 2021 , 2, 100325	1
688	Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing. 2021 , 10, e12076	25
687	The CREB Regulated Transcription Coactivator 2 Suppresses HIV-1 Transcription by Preventing RNA Pol II from Binding to HIV-1 LTR. 2021 , 36, 796-809	
686	Sec24C is an HIV-1 host dependency factor crucial for virus replication. 2021 , 6, 435-444	13
685	Current Approaches for Glioma Gene Therapy and Virotherapy. 2021 , 14, 621831	16
684	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.	2
683	A purine loop and the primer binding site are critical for the selective encapsidation of mouse mammary tumor virus genomic RNA by Pr77Gag. 2021 , 49, 4668-4688	1
682	Neuromuscular Junction Model Optimized for Electrical Platforms. 2021 , 27, 242-252	1
681	Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches. 2021 , 118,	2
680	Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development. 2021 , 11,	5
679	Hepatitis C virus infection restricts human LINE-1 retrotransposition in hepatoma cells. 2021 , 17, e1009496	2
678	Genetic modification of mesenchymal stem cells to enhance their anti-tumor efficacy. 2021 , 1-6	

677	Gene Therapy: A Possible Alternative to CFTR Modulators?. 2021 , 12, 648203	1
676	Unresolved Issues in RNA Therapeutics in Vascular Diseases With a Focus on Aneurysm Disease. 2021 , 8, 571076	0
675	SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques. 2021 ,	1
674	A Small-Scale shRNA Screen in Primary Mouse Macrophages Identifies a Role for the Rab GTPase Rab1b in Controlling Typhi Growth. 2021 , 11, 660689	1
673	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. 2021 , 29, 529-539.e3	225
672	An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity.	42
671	Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease. 2021 , 750, 135769	4
670	Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects. 2021 , 171, 109-121	0
669	Dynamin controls neuropeptide secretion by organizing dense-core vesicle fusion sites. 2021 , 7,	4
668	Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction. 2021 , 23, 452-458	0
667	Low RECK Expression Is Part of the Cervical Carcinogenesis Mechanisms. <i>Cancers</i> , 2021 , 13,	6.6 0
666	Evaluation of HIV-1 derived lentiviral vectors as transducers of Mucopolysaccharidosis type IV a fibroblasts. 2021 , 780, 145527	0
665	Optimization of the Light-On system in a lentiviral platform to a light-controlled expression of genes in neurons. 2021 , 51, 50-57	
664	Establishment of pan-Influenza A (H1-H18) and pan-Influenza B (pre-split, Vic/Yam) Pseudotype Libraries for efficient vaccine antigen selection.	
663	Intracerebral Administration of Autologous Mesenchymal Stem Cells as HSV-TK Gene Vehicle for Treatment of Glioblastoma Multiform: Safety and Feasibility Assessment. 2021 , 58, 4425-4436	1
662	Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. 2021 , 12, 673699	4
661	Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies. 2021 , 12, 661379	5
660	Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges. 2021 , 8, 662331	3

659	Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain. 2021 , 22,	7
658	Viral Vector Delivery of DREADDs for CNS Therapy. 2021 , 21, 191-206	1
657	HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency. 2021 , 11, 12067	0
656	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. 2021 , 21, 741-751	2
655	Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment. 2021 , 23, 483-496	
654	Host cellular RNA helicases regulate SARS-CoV-2 infection.	
653	Engineering Gene Therapy: Advances and Barriers. 2021 , 4, 2100040	2
652	Mesenchymal Stem Cells Pretreatment With Stromal-Derived Factor-1 Alpha Augments Cardiac Function and Angiogenesis in Infarcted Myocardium. 2021 , 361, 765-775	5
651	HIV-based lentiviral vectors: origin and sequence differences. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 21, 451-465	6.4 2
650	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. 2021 , 6,	12
649	Novel Role of UHRF1 in DNA methylation-mediated repression of latent HIV-1.	0
648	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. 2021 , 95, e0020321	7
647	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. 2021 , 29, 1124-1136.e11	147
646	The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. 2021 , 12, 701636	1
645	HIV Modifies the m6A and m5C Epitranscriptomic Landscape of the Host Cell. 2021 , 1,	0
644	Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs. 2021 , 23, e3377	2
643	Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection. 2021 , 9,	2
642	delivery of CRISPR-Cas9 therapeutics: Progress and challenges. 2021 , 11, 2150-2171	17

641	Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. 2021 , 13,	5
640	Improved Functionality of Integration-Deficient Lentiviral Vectors (IDLVs) by the Inclusion of IS Protein Docks. <i>Pharmaceutics</i> , 2021 , 13,	6.4 0
639	CAR T cells: Building on the CD19 paradigm. 2021 , 51, 2151-2163	9
638	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. 2021 , 69, 471-486	4
637	In Utero Gene Therapy for Primary Immunodeficiencies. 2021 , 64, 886-897	0
636	Mapping brain-wide excitatory projectome of primate prefrontal cortex at submicron resolution: relevance to diffusion tractography.	
635	The Engineered MARCH8-Resistant Vesicular Stomatitis Virus Glycoprotein Enhances Lentiviral Vector Transduction. 2021 , 32, 936-948	
634	Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation. 2021 ,	1
633	Stability and conformation of the dimeric HIV-1 genomic RNA 5'UTR. 2021 , 120, 4874-4890	2
632	Neuronal Differentiation-Related Epigenetic Regulator Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. <i>Cancers</i> , 2021 , 13,	6.6
631	Combining protein and RNA quantification to evaluate promoter activity by using dual-color fluorescent reporting systems. 2021 , 41,	2
630	Viral vector-based gene therapies in the clinic.. 2022 , 7, e10258	8
629	Antigen identification and high-throughput interaction mapping by reprogramming viral entry.	0
628	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. 2021 , 6,	15
627	Influenza A (N1-N9) and Influenza B (B/Vic and B/Yam) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine design.	
626	Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation. 2021 ,	1
625	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. 2021 , 297, 101127	2
624	The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells. 2021 , 12, 730873	0

623	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 23, 263-275	6.4	2
622	Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 23, 334-347	6.4	1
621	Drug delivery systems based on blood cells. 2022 , 167-193		
620	Pediatric Bone Marrow Transplantation. 2021 , 577-616		
619	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. 2021 ,		29
618	eNOS-dependent S-nitrosylation of the NF- κ B subunit p65 has neuroprotective effects. 2021 , 12, 4		7
617	Management of inborn errors of immunity. 2021 , 345-361		
616	Supramolecular virus-like particles by co-assembly of triblock polypeptide and PAMAM dendrimers. 2021 , 17, 5044-5049		3
615	Cold sensitivity of the SARS-CoV-2 spike ectodomain. 2021 , 28, 128-131		34
614	Somatic Cell Gene Transfer.		3
613	Imaging neural stem cell fate in mouse model of glioma. 2009 , Chapter 5, Unit 5A.1		9
612	Lentiviral Vector Mediated Transgenesis. 2011 , 1, 169-84		6
611	Overexpression Models: Lentiviral Modeling of Brain Cancer. 2013 , 3, 121-39		4
610	Retroviral Integration Target Site Selection. 51-65		1
609	Gene technology based therapies in the brain. 2006 , 31, 3-32		6
608	Gene therapy of atherosclerosis. 2005 , 785-807		2
607	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. <i>Methods in Molecular Biology</i> , 2020 , 2121, 213-239	1.4	7
606	Gene Therapy for Leukemia and Lymphoma. 2010 , 81-89		1

605	Stem Cells: The Holy Grail of Regenerative Medicine. 2014 , 19-69		2
604	Prospects for Designing Universal Stem Cell Lines. 2013 , 147-173		2
603	Hematopoietic Stem Cell Gene Therapy for Lysosomal Storage Disorders: Expected Benefits and Limitations. 2013 , 127-138		1
602	Gene therapy for Leber congenital amaurosis. 2003 , 533, 415-22		2
601	Invasive drug delivery. 2002 , 513, 431-51		9
600	Growth and genetic modification of human beta-cells and beta-cell precursors. 2000 , 22, 99-120		3
599	Retroviral Vectors. 1999 , 57-88		1
598	Genetic Approaches to Therapy for the Hemoglobinopathies. 1999 , 219-242		4
597	Gene Marking and the Biology of Hematopoietic Cell Transfer in Human Clinical Trials. 1999 , 243-268		5
596	HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. 1997 , 3, 21-7		17
595	Gene Therapy Vectors. 2014 , 27-33		1
594	Retroviral transduction of murine and human hematopoietic progenitors and stem cells. <i>Methods in Molecular Biology</i> , 2014 , 1185, 287-309	1.4	6
593	Lentiviral gene transduction of mouse and human hematopoietic stem cells. <i>Methods in Molecular Biology</i> , 2014 , 1185, 311-9	1.4	11
592	Utilization of a lentiviral system for the generation of B cells with regulatory properties. <i>Methods in Molecular Biology</i> , 2014 , 1190, 105-13	1.4	2
591	Examination of the role of galectins in plasma cell differentiation. <i>Methods in Molecular Biology</i> , 2015 , 1207, 153-67	1.4	3
590	Gene Delivery to Neurons of the Dorsal Root Ganglia Using Adeno-Associated Viral Vectors. 2015 , 175-189		1
589	Methods to immobilize GPCR on the surface of SPR sensors. <i>Methods in Molecular Biology</i> , 2015 , 1272, 173-88	1.4	7
588	Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins. <i>Methods in Molecular Biology</i> , 2017 , 1628, 65-78	1.4	10

587	Cell Type-Specific Targeting Strategies for Optogenetics. 2018 , 25-42		4
586	Overcoming Challenges of Hepatitis C Virus Envelope Glycoprotein Production in Mammalian Cells. <i>Methods in Molecular Biology</i> , 2019 , 1911, 305-316	1.4	1
585	Gene Therapy for Ischemic Stroke. 1998 , 397-408		2
584	Labeling and Identifying Grafted Cells. 2000 , 319-361		10
583	Intracerebral Gene Transfer Using Viral Vectors. 2000 , 103-130		1
582	Viral Vectors for Gene Therapy. 1999 , 69-105		9
581	Lentivirus-mediated gene expression. <i>Methods in Molecular Biology</i> , 2007 , 366, 343-55	1.4	16
580	Somatic cell genetic analyses to identify HIV-1 host restriction factors. <i>Methods in Molecular Biology</i> , 2009 , 485, 235-55	1.4	3
579	Rapid, controlled and intensive lentiviral vector-based RNAi. <i>Methods in Molecular Biology</i> , 2009 , 485, 257-70	1.4	9
578	Methods of preparation and analysis of intracellular reverse transcription complexes. <i>Methods in Molecular Biology</i> , 2009 , 485, 107-19	1.4	4
577	Gene Transfer for Chemoprotection and Enrichment of Hematopoietic Stem Cells. 2007 , 257-279		1
576	Applications of lentiviral vectors in noninvasive molecular imaging. <i>Methods in Molecular Biology</i> , 2008 , 433, 177-202	1.4	9
575	Cells for Gene Therapy and Vector Production. 2007 , 23-91		5
574	In situ (in vivo) gene transfer into murine bone marrow stem cells. <i>Methods in Molecular Biology</i> , 2009 , 506, 159-69	1.4	5
573	Detection of replication competent retrovirus and lentivirus. <i>Methods in Molecular Biology</i> , 2009 , 506, 243-63	1.4	13
572	Lineage analysis of inner ear cells using genomic tags for clonal identification. <i>Methods in Molecular Biology</i> , 2009 , 493, 47-63	1.4	5
571	Production of multicistronic HIV-1 based lentiviral vectors. <i>Methods in Molecular Biology</i> , 2009 , 515, 137-50	1.4	6
570	The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. <i>Methods in Molecular Biology</i> , 2009 , 542, 5-54	1.4	27

569	Reducing the genotoxic potential of retroviral vectors. <i>Methods in Molecular Biology</i> , 2008 , 434, 183-203	1.4	10
568	The use of lentiviral vectors to obtain transgenic rats. <i>Methods in Molecular Biology</i> , 2010 , 597, 109-25	1.4	15
567	Detecting and modulating the NF-kB activity in human immune cells: generation of human cell lines with altered levels of NF-kappaB. <i>Methods in Molecular Biology</i> , 2009 , 512, 39-54	1.4	3
566	Progress in the therapeutic applications of siRNAs against HIV-1. <i>Methods in Molecular Biology</i> , 2009 , 487, 343-68	1.4	13
565	Lentivirus-expressed siRNA vectors against Alzheimer disease. <i>Methods in Molecular Biology</i> , 2010 , 614, 215-24	1.4	17
564	Strategies to insulate lentiviral vector-expressed transgenes. <i>Methods in Molecular Biology</i> , 2010 , 614, 77-100	1.4	14
563	A new approach for therapeutic use by RNA interference in the brain. <i>Methods in Molecular Biology</i> , 2010 , 623, 313-24	1.4	4
562	Lentiviral vectors to study the differential function of ERK1 and ERK2 MAP kinases. <i>Methods in Molecular Biology</i> , 2010 , 661, 205-20	1.4	20
561	Regulation of monocytopoiesis by microRNAs. <i>Methods in Molecular Biology</i> , 2010 , 667, 165-76	1.4	2
560	Imaging fate of stem cells at a cellular resolution in the brains of mice. <i>Methods in Molecular Biology</i> , 2011 , 680, 91-101	1.4	1
559	Lentiviral fluorescent protein expression vectors for biotinylation proteomics. <i>Methods in Molecular Biology</i> , 2011 , 699, 431-47	1.4	3
558	RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy. <i>Methods in Molecular Biology</i> , 2011 , 721, 293-311	1.4	22
557	Lentiviral gene transfer method to study integrin function in T lymphocytes. <i>Methods in Molecular Biology</i> , 2012 , 757, 47-54	1.4	1
556	Generation of lentiviral vectors for use in skeletal muscle research. <i>Methods in Molecular Biology</i> , 2012 , 798, 285-95	1.4	3
555	Identification of stem cells after transplantation. <i>Methods in Molecular Biology</i> , 2013 , 1036, 89-94	1.4	2
554	Lentiviral Vectors as Research Tools in Neurobiology: Design and Production. 2014 , 3-10		1
553	Lentiviral Vectors in Huntington's Disease Research and Therapy. 2014 , 193-220		1
552	SIVSM/HIV-2 Vpx proteins: function and uses in the infection of primary myeloid cells. <i>Methods in Molecular Biology</i> , 2014 , 1087, 159-65	1.4	1

551	Efficient transduction of hematopoietic stem cells and its potential for gene correction of hematopoietic diseases. <i>Methods in Molecular Biology</i> , 2014 , 1114, 441-50	1.4	4
550	Gene therapy for inflammatory diseases [basic concepts]. 2000 , 1-11		1
549	Genome-Wide Genetic Screening in the Mammalian CNS. 2017 , 31-39		1
548	Generation of Transgenic Animals Using Lentiviral Vectors. 2006 , 1-22		5
547	Targeting retroviral and lentiviral vectors. 2003 , 281, 137-78		69
546	Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer. 1998 , 144, 93-115		9
545	The use of ribozymes in gene therapy approaches to AIDS. 1998 , 144, 139-46		4
544	Foamy virus vectors. 2003 , 277, 131-59		33
543	Lentiviruses as vectors for CNS diseases. 2002 , 261, 191-209		26
542	Lentiviral vectors for the gene therapy of lympho-hematological disorders. 2002 , 261, 211-27		13
541	Opportunities for the use of lentiviral vectors in human gene therapy. 2002 , 261, 245-54		45
540	Lentiviral vectors derived from simian immunodeficiency virus. 2002 , 261, 53-74		20
539	Nonprimate lentiviral vectors. 2002 , 261, 75-105		12
538	Lentiviral vector targeting. 2002 , 261, 143-63		5
537	Gene Therapy: Promises, Problems and Prospects. 2000 , 147-157		9
536	Cancer Vaccines. 1999 , 463-478		3
535	Lentiviral vectors for the genetic modification of hematopoietic stem cells. 2001 , 19-28		2
534	The future of gene therapy. 2003 , 1-16		3

533	Viral Vectors for HIV Gene Therapy. 1998 , 59-75	1
532	Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. 2000 , 181-91	7
531	Recent Advances in ALS Research: Perspectives for Personalized Clinical Application. 2013 , 235-274	1
530	Chitosan-Based Systems for Gene Delivery. 2019 , 229-267	5
529	Gene Therapy in Tissue Engineering. 1998 , 278-310	1
528	Gene Therapy of Ovarian Cancer—State-of-the-Art and Future Perspectives. 2003 , 277-304	1
527	Nonhuman Primate Models for Testing Gene Therapy for Neurodegenerative Disorders. 2006 , 109-119	1
526	Retroviral Vector Design for Cancer Gene Therapy. 2002 , 3-29	1
525	Protection from Antifolate Toxicity by Expression of Drug-Resistant Dihydrofolate Reductase. 2002 , 383-392	2
524	Genetic Engineering for CNS Regeneration. 1999 , 251-291	5
523	Thérapie génique de l'adréoleucodystrophie liée à l'IL13 par transfert du gène dans les cellules souches hématopoïétiques à l'aide d'un vecteur lentiviral. 2010 , 194, 255-268	2
522	Genetic immunotherapy for cancer. 1997 , 12, 193-205	7
521	Efficient transgenesis in farm animals by lentiviral vectors. 2003 , 4, 1054-1058	83
520	Development of gene therapy for hematopoietic stem cells using lentiviral vectors.	1
519	Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. 2000 , 97, 3038-43	23
518	Gene therapy for Parkinson's disease: contemporary practice and emerging concepts. 2020 , 20, 577-590	6
517	Downstream Processing of Lentiviral Vectors: releasing bottlenecks. 121017063203000	1
516	Restricted transgene expression in the brain with cell-type specific neuronal promoters. 121017063203000	3

515	Gene therapy. 2004 , 409-430	5
514	GENE THERAPY FOR PROSTATE CANCER:. 2001 , 1220-1233	2
513	Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4lg. 1999 , 67, 1607-13	43
512	Fetal tissue transplantation [correction of transplanation] in Parkinson's disease. 1998 , 11, 341-9	38
511	Human amniotic epithelial cells ameliorate behavioral dysfunction and reduce infarct size in the rat middle cerebral artery occlusion model. 2008 , 29, 603-11	76
510	Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation. 2001 , 82, 425-434	18
509	Requirements for RNA heterodimerization of the human immunodeficiency virus type 1 (HIV-1) and HIV-2 genomes. 2002 , 83, 2533-2542	19
508	Microinjection of lentiviral vectors expressing small interfering RNAs directed against laminin receptor precursor mRNA prolongs the pre-clinical phase in scrapie-infected mice. 2009 , 90, 269-74	16
507	Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. 2008 , 89, 2204-2213	82
506	A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells. 2006 , 87, 3587-3598	6
505	Persistent telomere cohesion protects aged cells from premature senescence.	1
504	Cold sensitivity of the SARS-CoV-2 spike ectodomain. 2020 ,	6
503	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.	21
502	SARS-CoV-2 infects brain choroid plexus and disrupts the blood-CSF-barrier.	10
501	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2.	2
500	Characterisation of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins.	1
499	The N-end rule E3 ligase UBR2 activates Nlrp1b inflammasomes.	1
498	Deciphering the protein dynamics and molecular determinants of iPSC-derived neurons.	1

497	Spontaneous Mutations in HIV-1 Gag, protease, RT p66 in the first replication cycle and how they appear: Insights from an in vitro BSL2 assay on mutation rates and types.	5
496	Efficient CRISPR/Cas9 genome editing in a salmonid fish cell line using a lentivirus delivery system.	2
495	Lentivirus transduction of hematopoietic cells. 2007 , 2007, pdb.prot4755	5
494	Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. 1996 , 70, 8098-108	711
493	Targeted adenovirus-mediated gene delivery to T cells via CD3. 1997 , 71, 7663-9	91
492	Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. 1997 , 71, 1155-61	92
491	Replication-competent chimeric lenti-oncovirus with expanded host cell tropism. 1997 , 71, 3328-31	18
490	Human immunodeficiency virus type 2 preintegration complexes: activities in vitro and response to inhibitors. 1997 , 71, 3351-6	20
489	Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. 1997 , 71, 4071-8	28
488	The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. 1997 , 71, 5841-8	86
487	Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. 1997 , 71, 5871-7	295
486	Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. 1997 , 71, 6174-8	61
485	Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. 1997 , 71, 6339-47	151
484	Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. 1997 , 71, 6641-9	556
483	Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements. 1997 , 71, 6834-41	22
482	Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. 1998 , 72, 811-6	189
481	Effect of host modification and age on airway epithelial gene transfer mediated by a murine leukemia virus-derived vector. 1998 , 72, 8861-72	38
480	High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. 1998 , 72, 8873-83	233

479	Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. 1998 , 72, 9683-97	61
478	Human immunodeficiency virus type 1 matrix protein interacts with cellular protein HO3. 1998 , 72, 1671-6	29
477	Chimeric measles viruses with a foreign envelope. 1998 , 72, 2150-9	106
476	Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. 1998 , 72, 3161-8	265
475	The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. 1998 , 72, 3178-84	41
474	Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. 1998 , 72, 5781-8	148
473	Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. 1998 , 72, 6307-14	57
472	Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. 1998 , 72, 6527-36	81
471	Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. 1999 , 73, 8919-25	118
470	Incorporation of wild-type and C-terminally truncated human epidermal growth factor receptor into human immunodeficiency virus-like particles: insight into the processes governing glycoprotein incorporation into retroviral particles. 1999 , 73, 9294-302	14
469	A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. 1999 , 73, 9589-98	28
468	Association of murine leukemia virus pol with virions, independent of Gag-Pol expression. 1999 , 73, 9632-7	12
467	Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus. 1999 , 73, 10329-38	71
466	Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. 1999 , 73, 1964-73	185
465	Lentivirus vectors using human and simian immunodeficiency virus elements. 1999 , 73, 2832-40	83
464	Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. 1999 , 73, 3649-60	164
463	Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. 1999 , 73, 4991-5000	156
462	Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. 1999 , 73, 6171-6	44

461	The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. 1999 , 73, 6708-14	34
460	Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. 1999 , 73, 7087-92	94
459	The presence of human immunodeficiency virus type 1 Vpr correlates with a decrease in the frequency of mutations in a plasmid shuttle vector. 1999 , 73, 7132-7	16
458	An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. 1999 , 73, 7671-7	63
457	Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. 1999 , 73, 7812-6	167
456	Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. 2016 , 1,	56
455	Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. 1997 , 100, 620-8	28
454	Gene therapy and genome surgery in the retina. 2018 , 128, 2177-2188	76
453	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. 2004 , 114, 77-84	133
452	Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression. 2007 , 117, 2672-83	36
451	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. 2007 , 117, 1037-48	100
450	Gene therapy for severe combined immunodeficiency: are we there yet?. 2007 , 117, 1456-65	169
449	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. 2008 , 118, 1750-64	42
448	Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. 2010 , 120, 379-89	52
447	The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. 2009 , 119, 964-75	407
446	Preventing and exploiting the oncogenic potential of integrating gene vectors. 2009 , 119, 755-8	38
445	Status of gene therapy for cystic fibrosis lung disease. 1999 , 103, 441-5	104
444	Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. 1999 , 104, R55-62	125

443	Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. 2017 , 127, 1005-1018	60
442	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. 2000 , 2000, 241-265	7
441	Gene Therapy 2000. 2000 , 2000, 376-393	4
440	Gene Therapy 2000. 2000 , 2000, 376-393	1
439	Functional Heterogeneity of Human CD34+ Cells Isolated in Subcompartments of the G0 /G1 Phase of the Cell Cycle. 1997 , 90, 4384-4393	8
438	Robust, But Transient Expression of Adeno-Associated Virus-Transduced Genes During Human T Lymphopoiesis. 1997 , 90, 4854-4864	14
437	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. 1998 , 92, 3537-3545	12
436	Development of lentiviral vectors for gene therapy for human diseases. 2000 , 95, 2499-2504	41
435	Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to Moloney murine leukemia virusBased vectors. 2000 , 96, 3385-3391	10
434	High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. 2000 , 96, 3392-3398	65
433	Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. 2000 , 96, 3725-3733	16
432	The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. 2000 , 96, 4103-4110	54
431	Therapeutic levels of human factor VIII and IX using HIV-1Based lentiviral vectors in mouse liver. 2000 , 96, 1173-1176	28
430	Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. 2000 , 96, 1206-1214	25
429	Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. 2000 , 96, 1309-1316	20
428	Lentivirus-Based Genetic Manipulations in Neurons In Vivo. 2006 , 249-259	5
427	Molecular and Cellular Biology of Derman Fibroproliferative Disorders. 2000 , 173-211	1
426	Efficient liver gene transfer with foamy virus vectors. 2013 , 19, 214-20	5

425	HIV-mediated expression of Btk in hematopoietic stem cells is not sufficient to restore B cell function in X-linked immunodeficient mice. 2005 , 72, 203-12	2
424	Recruitment and activation of RSK2 by HIV-1 Tat. 2007 , 2, e151	16
423	A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. 2008 , 3, e1828	36
422	Surfactants as microbicides and contraceptive agents: a systematic in vitro study. 2008 , 3, e2913	46
421	SGNP: an essential Stress Granule/Nucleolar Protein potentially involved in 5.8s rRNA processing/transport. 2008 , 3, e3716	20
420	A novel and efficient gene transfer strategy reduces glial reactivity and improves neuronal survival and axonal growth in vitro. 2009 , 4, e6227	39
419	Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. 2009 , 4, e6314	44
418	MS4a4B, a CD20 homologue in T cells, inhibits T cell propagation by modulation of cell cycle. 2010 , 5, e13780	19
417	Rab27a is required for human cytomegalovirus assembly. 2010 , 5, e15318	42
416	Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse. 2011 , 6, e16908	10
415	Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. 2011 , 6, e17821	19
414	Infection of XC cells by MLVs and Ebola virus is endosome-dependent but acidification-independent. 2011 , 6, e26180	17
413	Pigment epithelium-derived factor (PEDF) interacts with transportin SR2, and active nuclear import is facilitated by a novel nuclear localization motif. 2011 , 6, e26234	23
412	Genetic labeling of neuronal subsets through enhancer trapping in mice. 2012 , 7, e38593	12
411	Zinc-finger antiviral protein inhibits XMRV infection. 2012 , 7, e39159	27
410	Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. 2012 , 7, e43031	213
409	Sequences within both the 5' UTR and Gag are required for optimal in vivo packaging and propagation of mouse mammary tumor virus (MMTV) genomic RNA. 2012 , 7, e47088	16
408	Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage. 2012 , 7, e49566	37

407	Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. 2012 , 7, e50859	119
406	A transgenic tri-modality reporter mouse. 2013 , 8, e73580	11
405	Inhibition of HIV-1 replication by balsamin, a ribosome inactivating protein of Momordica balsamina. 2013 , 8, e73780	20
404	A constitutively active G β protein corrects the abnormal retinal pigment epithelium phenotype of Oa1 ^{-/-} mice. 2013 , 8, e76240	5
403	A modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivo. 2013 , 8, e76279	10
402	RNA control of HIV-1 particle size polydispersity. 2014 , 9, e83874	11
401	Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice. 2014 , 9, e97270	15
400	Oral and vaginal epithelial cell lines bind and transfer cell-free infectious HIV-1 to permissive cells but are not productively infected. 2014 , 9, e98077	24
399	In vivo molecular imaging and radionuclide (¹³¹ I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter. 2015 , 10, e0116531	6
398	Oviduct-specific expression of human neutrophil defensin 4 in lentivirally generated transgenic chickens. 2015 , 10, e0127922	19
397	Tomosyn associates with secretory vesicles in neurons through its N- and C-terminal domains. 2017 , 12, e0180912	6
396	Reduction in skeletal muscle fibrosis of spontaneously hypertensive rats after laceration by microRNA targeting angiotensin II receptor. 2017 , 12, e0186719	3
395	A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. 2016 , 12, e1005421	43
394	Single-cell analysis identifies cellular markers of the HIV permissive cell. 2017 , 13, e1006678	35
393	Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. 2017 , 13, e1006735	46
392	Stability of Retroviral Vectors Against Ultracentrifugation Is Determined by the Viral Internal Core and Envelope Proteins Used for Pseudotyping. 2017 , 40, 339-345	9
391	Mesenchymal stem cells from human amniotic membrane differentiate into cardiomyocytes and endothelial-like cells without improving cardiac function after surgical administration in rat model of chronic heart failure. 2019 , 11, 35-42	8
390	Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. 2002 , 22, 3473-83	162

389	Use of Retroviral and Lentiviral Vectors to Deliver New Gene Therapies. 2017 , 5,	1
388	Stem Cell-Based Gene Therapy. 1997 , 2, 196-202	2
387	Gene Transfer Technology in Therapy: Current Applications and Future Goals. 1998 , 3, 225-236	6
386	Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. 2001 , 12, 2827-2831	33
385	Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. 2001 , 12, 1677-1684	71
384	Gamma-interferon-inducible, lysosome/endosome-localized thiolreductase, GILT, has anti-retroviral activity and its expression is counteracted by HIV-1. 2016 , 7, 71255-71273	11
383	Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. 2017 , 8, 26298-26311	8
382	Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. 2017 , 8, 23760-23774	14
381	STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. 2017 , 8, 78556-78572	5
380	Fucoidan inhibition of lung cancer in vivo and in vitro : role of the Smurf2-dependent ubiquitin proteasome pathway in TGF β receptor degradation. 2014 , 5, 7870-85	68
379	EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. 2015 , 6, 9766-80	22
378	Mutant AKT1-E17K is oncogenic in lung epithelial cells. 2015 , 6, 39634-50	21
377	MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. 2016 , 7, 9271-87	25
376	Advances in Gene Delivery Systems. 2011 , 25, 293-306	57
375	A Review of Theranostics Applications and Toxicities of Carbon Nanomaterials. 2019 , 20, 506-532	19
374	AAV's anatomy: roadmap for optimizing vectors for translational success. 2010 , 10, 319-340	75
373	Nano-enhanced Optical Gene Delivery to Retinal Degenerated Mice. 2019 , 19, 318-329	5
372	A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons with Oligonucleotide Therapeutics. 2017 , 7,	4

371	Generation of Luciferase-expressing Tumor Cell Lines. 2018 , 8,	8
370	Lentiviral vector-mediated transduction of adult neural stem/progenitor cells isolated from the temporal tissues of epileptic patients. 2020 , 23, 354-361	3
369	Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey () brains. 2017 , 38, 88-95	12
368	Layer, column and cell-type specific genetic manipulation in mouse barrel cortex. 2008 , 2, 64-71	22
367	Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types. 2020 , 22,	7
366	Virus-Like Particle Mediated CRISPR/Cas9 Delivery for Efficient and Safe Genome Editing. 2020 , 10,	10
365	NT4(Si)-p53(N15)-antennapedia induces cell death in a human hepatocellular carcinoma cell line. 2009 , 15, 5813-20	3
364	New therapeutic opportunities for hepatitis C based on small RNA. 2007 , 13, 4431-6	22
363	Osteogenic differentiation of human periodontal ligament stem cells expressing lentiviral NEL-like protein 1. 2012 , 30, 863-9	4
362	Multifunctional Nanomaterials for Multifaceted Applications in Biomedical Arena. 2017 , 13, 890-906	11
361	Gene therapy: principles and clinical applications in orthopedics. 2004 , 27, 294-303; quiz 304-5	8
360	Construction of a recombinant lentivirus containing human microRNA-7-3 and its inhibitory effects on glioma proliferation. 2012 , 7, 2144-50	3
359	Lentivirus carrying the Atoh1 gene infects normal rat cochlea. 2013 , 8, 1551-9	8
358	DNA as therapeutics; an update. 2009 , 71, 488-98	16
357	Lentiviral Based Gene Transduction and Promoter Studies in Human Hematopoietic Stem Cells (hHSCs). 2011 , 7, 41-53	18
356	Selection of RNAi-based inhibitors for anti-HIV gene therapy. 2012 , 1, 79-90	15
355	Gene therapy, early promises, subsequent problems, and recent breakthroughs. 2013 , 3, 249-55	22
354	Knockdown of a proliferation-inducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. 2012 , 13, 633-6	6

- 353 An alternative splicing program promotes adipose tissue thermogenesis. *ELife*, **2016**, 5, 8.9 32
- 352 HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors. *ELife*, **2019**, 8, 8.9 26
- 351 Hepatitis C virus exploits cyclophilin A to evade PKR. *ELife*, **2020**, 9, 8.9 8
- 350 Endemic Seasonal Coronavirus Neutralisation and COVID-19 severity.
- 349 Persistent Immunogenicity of Integrase Defective Lentiviral Vectors delivering membrane tethered Native-Like HIV-1 Envelope Trimers.
- 348 Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord. **2021**, 14, 695937 6
- 347 Use of lentiviral vectors in vaccination. **2021**, 1-16 2
- 346 Success Stories and Challenges Ahead in Hematopoietic Stem Cell Gene Therapy: Hemoglobinopathies as Disease Models. **2021**, 32, 1120-1137 1
- 345 Potential Gene Therapy Options for Early OA. **2022**, 321-337
- 344 A Stretch of Unpaired Purines in the Leader Region of Simian Immunodeficiency Virus (SIV) Genomic RNA is Critical for its Packaging into Virions. **2021**, 433, 167293 0
- 343 Retroviral Transfer and Expression of Drug Resistance Genes in Hematopoietic Cells. **2000**, 279-286
- 342 Basic Studies Toward Hematopoietic Stem Cell Gene Therapy. **2000**, 159-169
- 341 Retroviral vectors for cancer gene therapy. **2000**, 99-104
- 340 Vectors for Gene Transfer to Joints. **2000**, 245-259
- 339 Future Prospects of Gene Therapy for Treating CNS Diseases. **2000**, 485-508 1
- 338 Genetic Modulation of Effector Cells to Enhance GVL Effects. **2000**,
- 337 Ex vivo hepatocyte-directed gene therapy. **2000**, 503-520
- 336 Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. **2000**, 2000, 241-265 1

- 335 Gentherapie. **2000**, 847-853
- 334 Fetal hematopoietic stem cells: in vitro expansion and transduction using lentiviral vectors. **2001**, 123-44
- 333 T-bodies as antiviral agents. **2001**, 260, 271-300 5
- 332 Transient Transgenesis in The Endocrine System: Viral Vectors for Gene Delivery. **2001**, 195-232
- 331 Gene Therapy in Organ Transplantation: Applicabilities and Shortcomings. **2001**, 335-356
- 330 Lebergentherapie: Aktueller Stand und Ausblick. **2001**, 391-459
- 329 Gene Therapy Applications for the Treatment of Acute Inflammatory Conditions. **2001**, 225-246
- 328 Fetal gene therapy. **2001**, 1, 14-27
- 327 Genetic engineering of dendritic cells. **2001**, 609-cp1 1
- 326 Gene Transfer Strategies in Tissue Repair. **2001**, 117-137
- 325 Gene Therapeutic Approaches for ECell Replacement. **2001**, 373-400
- 324 Principles of gene transfer and foreign protein expression for human gene therapy. **2001**, 169-180
- 323 Gene Therapy for HIV Infection. **2001**, 471-492
- 322 Regulatory Aspects in Gene Therapy. **2002**, 289-310
- 321 Lentiviral vectors for gene therapy of HIV-induced disease. **2002**, 261, 229-43 2
- 320 Gene Therapy. **2002**, 1-27
- 319 Lentivirus: a vector for nervous system applications. **2003**, 179-207 3
- 318 Gene Transfer Strategies and Therapeutic Applications for Cardiovascular Ischemic Diseases. **2003**, 453-484

- 317 CNS diseases amenable to gene therapy. **2003**, 117-58
- 316 Methoden der Genübertragung. **2003**, 542-590
- 315 Gene Therapy in the Central Nervous System. **2003**, 173-186
- 314 Gene Therapy: Medicine of the 21st Century. **2003**, 159-172
- 313 Retrovectors Go Forward. **2003**,
- 312 Chimeric Gene Delivery Systems. **2003**,
- 311 Transduction of Human ES Cells by Lentiviral Vectors. **2004**, 557-563
- 310 Experimental Approaches to Hemophilia Gene Therapy: Gene Transfer into Hematopoietic Stem Cells. **2004**, 153-158
- 309 High Resolution Clonal Marking-Analysis. **2004**, 651-662
- 308 Novel Therapeutic Approaches for High-Grade Gliomas. **2004**, 155-180
- 307 Lentiviral Vector- Mediated Delivery of si/ shRNA. **2004**,
- 306 Selective Transduction of Malignant Glioma by Lentiviral Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoproteins. **2004**, 041101053234009
- 305 Animal Models in AIDS Research. **2004**, 61-77
- 304 A method for gene transfer, single isolation and in vitro assay for neural stem cells. **2005**, 25, 50-54
- 303 Prospects for Gene Therapy for Central Nervous System Disease. **2005**, 267-283
- 302 Gene Therapy of Storage Disorders by Retroviral and Lentiviral Vectors. **2005**, 050831054349001
- 301 Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors. **2005**, 050926062155001
- 300 Product-Enhanced Reverse Transcriptase Assay for Replication-Competent Retrovirus and Lentivirus Detection. **2005**, 050921065807001

- 299 Hematopoietic Stem Cell Transduction and Amplification in Large Animal Models. **2005**, 051111062524001
- 298 Lentiviral Biology and Cell Death. **2005**, 3-19
- 297 Gene Therapy to the Nervous System. **2006**, 133-154
- 296 Endogenous Wnt Signaling Promotes Proliferation and Suppresses Osteogenic Differentiation in Human Adipose Derived Stromal Cells. **2006**, 060210065733001
- 295 Gene Therapy for Heart Failure. **2006**, 573-588
- 294 Lentiviral Vectors Mediate Efficient and Stable Gene Transfer in Adult Neural Stem Cells In Vivo. **2006**, 060801084750007
- 293 Targeted Gene Modification of the Nervous System. **2006**, 75-99
- 292 Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. **2006**, 060801084750012
- 291 Gene Therapy Applications for Parkinson's Disease. **2006**, 141-184
- 290 Structure-Specific Patterns of Neural Stem Cell Engraftment After Transplantation in the Adult Mouse Brain. **2006**, 060801084750024
- 289 Lentiviral Manipulation of Gene Expression in Human Adult and Embryonic Stem Cells. **2006**, 060802052515029
- 288 Gene Therapy and Novel Clinical Trial Design. **2006**, 103-125
- 287 Gene Therapy Approaches in Neurology. **2007**, 101-123
- 286 Structural Genomics. **2007**, 1-27
- 285 Transduction Technologies. **2007**, 3-21
- 284 Gene Therapy for Platelet Disorders. **2007**, 1313-1325
- 283 Efficient Transduction of Simian Cells by HIV-1-based Lentiviral Vectors that Contain Mutations in the Capsid Protein.
- 282 Prospects for Gene Therapy. **2008**, 557-564

- 281 Use of Viral Gene Delivery Systems to Investigate the Neuroprotective Roles of Hsp70 and Hsp40 Proteins. **2008**, 223-237
- 280 Gene Therapy in Nonneoplastic Lung Disease. **2008**, 510-523
- 279 A Multicolor Panel of Novel Lentiviral Gene Ontology (LeGO) Vectors for Functional Gene Analysis. **2008**, 081126224950050
- 278 Gene Therapy for HIV Infection. 471-492
- 277 Lentiviral Vectors. **2008**,
- 276 Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of non-human primates. **2008**, 081126224950050
- 275 An improved Tet-on system for expression in neurons delivered by a single lentiviral vector. **2008**, 081124062308039
- 274 Gene Therapy and Viruses. **2009**, 351-370
- 273 Genetic Manipulation of Human Embryonic Stem Cells. **2009**, 75-86
- 272 Gene Therapy for Neurological Disorders (Except Oncology). **2009**, 3061-3082
- 271 Engineering Viruses for CNS studies. **2009**, 1059-1068
- 270 Viral Vectors for in Vivo Gene Transfer. **2009**, 1069-1096
- 269 Haemoglobin Disorders: Gene Therapy.
- 268 In Utero Muscle Gene Transfer. **2010**, 23-40
- 267 The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. **2010**, 122, 9-16
- 266 Chapter 7: Mesenchymal Stromal/Stem Cells from Tissue Repair to Destruction of Tumor Cells. **2010**, 141-158
- 265 Gene Therapy for Nonneoplastic Hematologic and Histiocytic Disorders. **2010**, 597-608
- 264 Hematopoietic Stem Cell Transplantation and Gene Therapy for Primary Immune Deficiency Diseases. **2010**, 223-231

263 Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy. **2011**, 251-278

262 Lentiviral vector delivery of shRNA into cultured primary myogenic cells: a tool for therapeutic target validation. *Methods in Molecular Biology*, **2011**, 709, 223-35

1.4 ○

261 Delivery Strategies for RNAi to the Nervous System. **2011**, 59-76

260 Generation of Transgenic Rats Using Microinjection of Plasmid DNA or Lentiviral Vectors. **2011**, 117-135

259 Reconstitution of the Myeloid and Lymphoid Compartments after the Transplantation of Autologous and Genetically Modified CD34+ Bone Marrow Cells, Following Gamma Irradiation in Cynomolgus Macaques. **2011**, 133-159

258 Priming of Hepatocytes Enhances In Vivo Liver Transduction with Lentiviral Vectors in Adult Mice. 110923093306005

257 Integrating Viral Vectors for Gene Modifications. 163-197

256 Development and Application of Membrane-Tethered Toxins for Genetic Analyses of Neuronal Circuits. **2012**, 141-164

255 RNAi-Mediated Therapeutics.

254 Development of Retroviral and Lentiviral Vectors. **2012**, 11-28

253 Cell and Tissue Gene Targeting with Lentiviral Vectors. **2012**, 29-50

252 Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A. **2011**, 1,

2

251 Leukemogenic Fusion Gene (p190 BCR-ABL) Transduction into Hematopoietic Stem/Progenitor Cells in the Common Marmoset. **2012**, 02, 1-10

250 Nanomagnetic Gene Transfection. **2012**, 333-350

249 Gene Therapy for Parkinson's. **2012**, 1119-1148

248 RRE-deleting self-inactivating and self-activating HIV-1 vectors for improved safety. **2013**, 1, e84

247 Imaging Migration and Fate of Stem Cells in Experimental Models of Cancer. 245-255

246 Breast Cancer Gene Therapy. **2014**, 519-534

245 Intercellular Immunization. **1997**, 85-104

244 Robust, But Transient Expression of Adeno-Associated Virus-Transduced Genes During Human T Lymphopoiesis. **1997**, 90, 4854-4864

243 Gene Therapy of a Rodent Model of Parkinson's Disease using Adeno-Associated Virus (AAV) Vectors. **1998**, 647-652

242 Single Chain Variable Fragment-Based Strategies for Anti-HIV-1 Gene Therapy: Targeting the Viral Preintegration Complex and Combination Molecular Approaches. **1998**, 183-208

241 Hematopoietic Ex Vivo Gene Transfer. **1998**, 195-210

240 Protection of Hematopoietic Progenitor Cells from Chemotherapy Toxicity by Transfer of Drug Resistance Genes. **1998**, 153-181

239 Lentiviral Vectors for Gene Delivery in the Nervous System. **1998**, 113-120

238 Neuroantibodies: The Use of Recombinant Antibody Expression in the Central Nervous System. **1998**, 75-96

237 EBV Vectors. **1998**, 93-112

236 Somatic Gene Transfer and Cell Transplantation Strategies for Neurodegenerative Diseases. **1998**, 303-331

235 HIV Vector Mediated Gene Transfer into CD4 Positive Cells. **1998**, 313-317

234 Retrovirus Vectors and Regulatable Promoters. **1998**, 7-38

1

233 Molekulare Grundlagen des Gentransfers und Anwendung für die Gentherapie. **1998**, 110-145

232 Retroviral Vectors for Human Gene Therapy. **1998**, 119-132

231 Strategies for Administering Neurotrophic Factors to the Central Nervous System. **1999**, 255-280

1

230 Prospects for Gene Therapy of Inherited Immunodeficiency. **1999**, 155-202

229 Future Perspectives of Gene Therapy for Gastric Cancer. **1999**, 187-193

228 Trophic Factors in Experimental Models of Adult Central Nervous System Injury. **1999**, 129-173

- 227 Somatic gene therapy in animal models of Parkinson's disease. **1999**, 55, 131-47 1
- 226 Characterization of Adenoviral Gene Expression in Spinal Cord after Remote Vector Delivery. **1999**, 45, 131 20
- 225 Gene Therapy. **1999**,
- 224 RNA interference: a promising therapy for gastric cancer. **2014**, 15, 5509-15 7
- 223 Viral Vectors for Gene Therapy. 1-16
- 222 Gene Therapy for Severe Haemoglobin Disorders.
- 221 Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models. **2015**, 341-354
- 220 Treating Hemophilia by Gene Therapy. **2016**, 179-201
- 219 S2 from Equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.
- 218 Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines. **2017**, 7,
- 217 Mono-ubiquitination of syntaxin 3 leads to retrieval from the basolateral plasma membrane and facilitates cargo recruitment to exosomes.
- 216 CBF-1 promotes the establishment and maintenance of HIV latency by recruiting Polycomb repressive complexes, PRC1 and PRC2, at HIV LTR.
- 215 Transgenes Application and Its Barriers in Contemporary Animal Husbandry. **2017**, 1,
- 214 Effects of lentivirus-mediated endostatin on endothelial progenitor cells. **2017**, 8, 94431-94439 2
- 213 Efficient lentiviral transduction of different human and mouse cells. 1
- 212 Regulatory Dysfunction inhibits the Development and Application of Transgenic Livestock for Use in Agriculture. **2018**, 149-167 1
- 211 Genetic Flexibility of the NKNK Motif in HIV-1 Integrases Allows Its Involvement in Multiple Functions During Infection.
- 210 Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly.

- 209 Re-Targeting of MacroH2A Following Mitosis to Cytogenetic-Scale Heterochromatic Domains.
- 208 Gene augmentation and read-through rescue channelopathy in an iPSC-RPE model of congenital blindness.
- 207 Pharmacodynamic Evaluation: Gene Therapy. **2019**, 1-24
- 206 Nano-enhanced optical gene delivery to retinal degenerated mice.
- 205 Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases and Its Implications for Future Gene Therapy Trials in Turke.
- 204 SULTA4A1 modulates synaptic development and function by promoting the formation of PSD-95/NMDAR complex. 1
- 203 Heparanase-2 protects from endothelial injury by inhibiting TLR4 signaling.
- 202 Molecular Cloning, Lentiviral Transduction, and Expression of Recombinant ADAMTSL2 and ADAMTSL4. *Methods in Molecular Biology*, **2020**, 2043, 137-155 1.4
- 201 Cerebellar plasticity and associative memories are controlled by perineuronal nets.
- 200 A novel toolkit for the efficient delivery of Cas9/sgRNA complexes to chromosomes in cells.
- 199 HIV-1 Rev interacts with HERV-K RcREs present in the human genome and promotes export of unspliced HERV-K proviral RNA.
- 198 Optogenetics: Novel Brain Interface Technology That Originates in Bioprospecting. **2020**, 293-313
- 197 Pharmacodynamic Evaluation: Gene Therapy. **2020**, 361-384
- 196 Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs.
- 195 Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. 0
- 194 Retrograde transport defects in Munc18-1 null neurons explain abnormal Golgi morphology.
- 193 Genetically flexible but conserved: a new essential motif in the C-ter domain of HIV-1 group M integrases.
- 192 Potential for virus endogenization in humans through testicular germ cell infection: the case of HIV. 1

- 191 Efficient Transduction of T-Lymphocytes by Lentiviral Particles in Oncoimmunological Studies. **2020**, 13, 295-306
- 190 A small-scale shRNA screen in primary mouse macrophages identifies a role for the Rab GTPase Rab1b in controlling Salmonella Typhi growth. 1
- 189 Vaccines as Immunotherapy. **2021**, 31-61 o
- 188 Pediatric Bone Marrow Transplantation. **2020**, 1-41
- 187 Gene Therapy and its Application in Dermatology. **2020**, 65, 341-350 o
- 186 A synthetic synaptic organizer protein restores glutamatergic neuronal circuits.
- 185 Lentivirus-mediated Conditional Gene Expression. **2021**, 11, e4205
- 184 A synthetic gene circuit for imaging-free detection of signaling pulses. **2021**, 2
- 183 An innate contribution of human nicotinic receptor polymorphisms to COPD-like lesions. *Nature Communications*, **2021**, 12, 6384 17.4 o
- 182 SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity. **2021**, 1
- 181 Gene Therapy for Neuromuscular Disorders: Macrophages as Shuttles for Widespread Targeting. **1998**, 531-539
- 180 Gene Therapeutic Enhancement of Animal Health and Performances. **2001**, 143-157
- 179 Therapy for Fanconi Anemia. **2006**, 92-102
- 178 The Potential for Gene Therapy of Neurodegenerative Disorders. **2004**, 259-267
- 177 Drug Resistance Gene Transfer as an Antitumor Strategy. **2005**, 321-333
- 176 Molecular Chemotherapy Approaches. **2005**, 109-128
- 175 Viral Vector Delivery to Dividing Cells. **2006**, 477-493
- 174 Generation of Transgenic Rats Using Microinjection of Plasmid DNA or Lentiviral Vectors. **2011**, 117-135 o

173	Probing Synaptic Signaling with Optogenetic Stimulation and Genetically Encoded Calcium Reporters. <i>Methods in Molecular Biology</i> , 2021 , 2191, 109-134	1.4	0
172	The DEAD box RNA helicase DDX42 is an intrinsic inhibitor of positive-strand RNA viruses.		0
171	Lentiviral Transduction for Optimal LSC/HSC Manipulation. <i>Methods in Molecular Biology</i> , 2021 , 2185, 299-306	1.4	
170	The Use of Peptide and Protein Vectors to Cross the Blood-Brain Barrier for the Delivery of Therapeutic Concentration of Biologics. 2021 , 119-147		
169	The Interaction of Munc18-1 Helix 11 and 12 with the Central Region of the VAMP2 SNARE Motif Is Essential for SNARE Templating and Synaptic Transmission. 2020 , 7,		3
168	Visualization of transfer of a fluorescently-labeled membrane raft protein to T cells using lentivirus. 2005 , 9B, 135-142		
167	Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. 1997 , 3, 466-76		14
166	Calcium phosphate coprecipitation greatly enhances transduction of cardiac myocytes and vascular smooth muscle cells by lentivirus vectors. 2007 , 12, 133-8		5
165	Overexpression of a mutant form of TGFBI/BIGH3 induces retinal degeneration in transgenic mice. 2008 , 14, 1129-37		17
164	[Enhanced control of proliferation in telomerized cells]. 2007 , 38, 105-19		6
163	Functional promoter testing using a modified lentiviral transfer vector. 2007 , 13, 730-9		8
162	Gene therapy to the kidney using viral vectors. 2008 , 71, 177-185		0
161	Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. 2011 , 2, 367-90		61
160	Production of CGMP-Grade Lentiviral Vectors. 2012 , 10, 32-43		50
159	Use of integrase-minus lentiviral vector for transient expression. 2012 , 14, 76-81		7
158	Expression of exogenous enhanced green fluorescent protein in rat endocranium through lentivirus infection. 2015 , 8, 7028-33		
157	Forced Complementation between Subgenomic RNAs: Does Human Immunodeficiency Type 1 Virus Reverse Transcription Occur in Viral Core, Cytoplasm, or Early Endosome?. 2015 , 1,		
156	Mesenchymal stem cells were affected by up-regulation of miRNA-21 in vitro. 2018 , 11, 27-37		1

155	[Construction and identification of recombinant lentivirus vector for microRNA-223 overexpression and suppression]. 2015 , 33, 451-5	1
154	[Research advances on gene therapy for hemophilia A]. 2015 , 36, 620-5	
153	Modeling synucleinopathies in rodents. 2021 , 2, 65-154	0
152	Associa� Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies. 2021 , 43 Suppl 2, S46-S53	
151	Different impact of bovine complement regulatory protein 46 (CD46) as a cellular receptor for members of the species and. 2021 , 1-38	0
150	Improved SARS-CoV-2 Spike Glycoproteins for Pseudotyping Lentiviral Vectors. 2021 , 1,	1
149	Antivirus activity, but not thiolreductase activity, is conserved in interferon-gamma-inducible GILT protein in arthropod. 2021 , 140, 240-249	0
148	Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. 2021 , 233, 108888	1
147	Gene Therapy for Acute Respiratory Distress Syndrome.. 2021 , 12, 786255	0
146	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift.. 2022 ,	5
145	Imaging Neuronal Activity in Cerebellar Cortex of Behaving. 2022 , 245-269	
144	AIE-active macromolecules: designs, performances, and applications. 2021 , 13, 8-43	1
143	HIV-1 Accessory Proteins Impart a Modest Interferon Response and Upregulate Cell Cycle-Related Genes in Macrophages.. 2022 , 11,	0
142	Gene Therapy Developments for Pompe Disease.. 2022 , 10,	2
141	Advances in genetic engineering of the avian genome. 2022 , 559-572	
140	Immunogenetics and the mapping of immunological functions. 2022 , 277-297	
139	Host cellular RNA helicases regulate SARS-CoV-2 infection.. 2022 , jvi0000222	2
138	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity.. 2022 ,	95

137	Optogenetic Animal Models of Depression: From Mice to Men. 2022 , 167-191	
136	High-content CRISPR screening. 2022 , 2,	10
135	Bioactive Graphene Quantum Dots Based Polymer Composite for Biomedical Applications.. 2022 , 14,	9
134	Cancer gene therapy goes viral: viral vector platforms come of age.. 2022 , 56, 1-13	3
133	Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications.. 2022 ,	5
132	Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasis.. 2022 , 177, 106119	4
131	SARS-CoV-2 Omicron spike mediated immune escape and tropism shift.	23
130	SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.. 2021 , 17, e1010175	4
129	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.. 2021 , 13,	7
128	VCN Analysis Using Droplet Digital PCR Method in Hematopoietic Stem Cells and T Lymphocytes after Lentiviral Transduction: Optimization and Limitations. 2022 , 2, 28-36	
127	Monitoring Virus-Induced Stress Granule Dynamics Using Long-Term Live-Cell Imaging.. <i>Methods in Molecular Biology</i> , 2022 , 2428, 325-348	1.4
126	Lentiviral Transduction of Mammary Epithelial Cells.. <i>Methods in Molecular Biology</i> , 2022 , 2471, 159-183	1.4
125	Engineering Novel Lentiviral Vectors for Labelling Tumour Cells and Oncogenic Proteins.. 2022 , 9,	
124	Rapid manufacturing of non-activated potent CAR T cells.. 2022 ,	7
123	Avances en terapia génica en humanos: algunos conceptos básicos y un recorrido histórico. 2022 , 33, 109-118	
122	Inhibiting presynaptic calcium channel mobility in the auditory cortex suppresses synchronized input processing.	0
121	Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.. 2022 , 11,	2
120	Immunological barriers to haematopoietic stem cell gene therapy.. 2022 ,	1

119	Gene Therapy for Cardiac Transplantation.		1
118	Clinical grade lentiviral vector purification and quality control requirements.. 2022 ,		0
117	Antigen identification and high-throughput interaction mapping by reprogramming viral entry.. 2022 ,		0
116	Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?. 2022 ,		1
115	Capturing the start point of the virus-cell interaction with high-speed 3D single-virus tracking.		0
114	Programmable in vivo CRISPR activation elucidates the oncogenic and immunosuppressive role of MYC in lung adenocarcinoma.		
113	Development, Production, and Characterization of Hepatitis B Subviral Envelope Particles as a Third-Generation Vaccine.. <i>Methods in Molecular Biology</i> , 2022 , 2410, 273-287	1.4	0
112	Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications.. 2021 , 106, 579		
111	A novel role for gag as a cis-acting element regulating RNA structure, dimerization and packaging in HIV-1 lentiviral vectors.. 2021 ,		
110	Selective packaging of HIV-1 RNA genome is guided by the stability of 5' untranslated region polyA stem. 2021 , 118,		2
109	Application of CRISPR/Cas9 in Alzheimer's Disease.. 2021 , 15, 803894		1
108	De novo missense variants in SLC32A1 cause a neurodevelopmental disorder with epilepsy due to impaired GABAergic neurotransmission.		
107	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.. 2021 , 11, 23921		10
106	Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.. 2021 , 41, 1052		4
105	Current view on novel vaccine technologies to combat human infectious diseases. 2021 , 106, 25		6
104	Localization of the Priming Factors CAPS1 and CAPS2 in Mouse Sensory Neurons Is Determined by Their N-Termini.. 2022 , 15, 674243		
103	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.. 2022 , 7, 44		0
102	Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2.. 2022 , 14,		0

101	Validation of reliable safe harbor locus for efficient porcine transgenesis.. 2022 , 1		1
100	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1.. 2022 , 79, 103985		0
99	Cellular replacement in spinal cord injury. 435-456		
98	Generation of Transgenic Animals Using Lentiviral Vectors. 2006 , 1-22		
97	Table_1.DOCX. 2020 ,		
96	Presentation_1.PDF. 2018 ,		
95	Table_1.XLSX. 2018 ,		
94	Image_1.jpg. 2019 ,		
93	Image_2.TIF. 2019 ,		
92	Image_3.JPEG. 2019 ,		
91	Image_4.JPEG. 2019 ,		
90	Introduction and overview of carbon nanomaterial-based sensors for sustainable response. 2022 , 395-416		0
89	The use of viral vectors to promote repair after spinal cord injury.. <i>Experimental Neurology</i> , 2022 , 114102,7		
88	Selective inhibition of miRNA processing by a herpesvirus-encoded miRNA.. 2022 , 605, 539-544		0
87	A ubiquitinome analysis to study the functional roles of the proteasome associated deubiquitinating enzymes USP14 and UCH37.. <i>Journal of Proteomics</i> , 2022 , 262, 104592	3.9	0
86	Mapping brain-wide excitatory projectome of primate prefrontal cortex at submicron resolution and comparison with diffusion tractography.. <i>ELife</i> , 2022 , 11,	8.9	0
85	Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. <i>Cell Reports</i> , 2022 , 39, 110859	10.6	2
84	Chondroitin sulfate proteoglycans prevent immune cell phenotypic conversion and inflammation resolution via TLR4 in rodent models of spinal cord injury. <i>Nature Communications</i> , 2022 , 13,	17.4	2

83	Characterization of an immune-evading doxycycline-inducible lentiviral vector for gene therapy in the spinal cord. <i>Experimental Neurology</i> , 2022 , 355, 114120	5.7	0
82	Zn (II)-Coordination-driven Self-assembled Nanoagents for Multimodal Imaging-Guided Photothermal/Gene Synergistic Therapy. <i>Chemical Science</i> ,	9.4	1
81	Retroviral Vectors for Gene Therapy of Monogenic Diseases. 2022 , 145-159		
80	Viral vector gene therapy approaches for regeneration and repair in spinal cord injury. 2022 , 411-423		
79	Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022 ,	6.4	0
78	Characterization of entry pathways, species-specific ACE2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants.		
77	Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy. <i>Methods in Molecular Biology</i> , 2022 , 297-315	1.4	1
76	A programmable in vivo CRISPR activation model elucidates the oncogenic and immunosuppressive functions of MYC in lung adenocarcinoma. <i>Cancer Research</i> ,	10.1	1
75	Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective. <i>Pharmaceutics</i> , 2022 , 14, 1287	6.4	2
74	CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease. <i>Pharmaceutics</i> , 2022 , 14, 1252	6.4	2
73	Human seasonal coronavirus neutralisation and COVID-19 severity. <i>Journal of Medical Virology</i> ,	19.7	0
72	Bioprospecting and bioassay-guided isolation of medicinal plantsA tool for drug discovery. 2022 , 511-537		
71	Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation. <i>Frontiers in Bioengineering and Biotechnology</i> , 10,	5.8	1
70	Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave. <i>Molecular Diagnosis and Therapy</i> , 2022 , 26, 353-367	4.5	
69	Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story. <i>Cancers</i> , 2022 , 14, 3238	6.6	0
68	Neuron-specific translational control shift ensures proteostatic resilience during ER stress. <i>EMBO Journal</i> ,	13	0
67	Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection.		1
66	Evaluation of Lentiviral Vector Stability and Development of Ion Exchange Purification Processes. <i>Biotechnology Progress</i> ,	2.8	1

65	Application of Small Molecules in the Central Nervous System Direct Neuronal Reprogramming. <i>Frontiers in Bioengineering and Biotechnology</i> , 10,	5.8	0
64	Therapeutic in vivo delivery of gene editing agents. <i>Cell</i> , 2022 ,	56.2	4
63	GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES. <i>Radiologic Clinics of North America</i> , 2000 , 20, 221-235.		
62	IDO1, FAT10, IFI6, and GILT Are Involved in the Antiretroviral Activity of Interferon and IDO1 Restricts Retrovirus Infection by Autophagy Enhancement. 2022 , 11, 2240		0
61	Lentiviral Vectors for Ocular Gene Therapy. 2022 , 14, 1605		0
60	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.		0
59	Integrase deficient lentiviral vector: prospects for safe clinical applications. 10, e13704		0
58	Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC. 2022 , 185, 3201-3213.e19		4
57	Genetic Modification of Primary Human Myeloid Cells to Study Cell Migration, Activation, and Organelle Dynamics. 2022 , 2,		1
56	Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency. 2022 , 19,		0
55	Cell type-programmable genome editing with enveloped delivery vehicles.		1
54	Harnessing nucleic acid technologies for human health on earth and in space. 2022 ,		0
53	Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern. 2022 , 25, 104935		2
52	Advanced drug delivery systems involving lysosomal storage disorders for Schindler disease and other disorders. 2022 , 281-299		0
51	Generation of In Vivo Traceable Hepatocyte-Like Cells from Human iPSCs. 2022 , 15-49		0
50	The DEAD box RNA helicase DDX42 is an intrinsic inhibitor of positive-strand RNA viruses.		0
49	HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo. 2022 , 11, 2968		0
48	CDKL5 regulates p62-mediated selective autophagy and host antiviral defense.		0

47	Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design. 2022 , 10, 1520	1
46	Targeted insertion of reporter transgene into a gene safe harbor in human blood fluke, <i>Schistosoma mansoni</i> .	0
45	Stimuli-Responsive Aggregation-Induced Emission (AIE)-Active Polymers for Biomedical Applications.	0
44	Delivering gene therapy for mucopolysaccharide diseases. 9,	0
43	De Novo Missense Variants in SLC32A1 Cause a Developmental and Epileptic Encephalopathy Due to Impaired GABAergic Neurotransmission.	0
42	Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years. 2022 , 29,	0
41	RNA Tumor Viruses. 1-14	0
40	Reduced Dynamin-I levels in neurons lacking MUNC18-1.	0
39	Role of the E3 ubiquitin-ligase Hakai in intestinal inflammation and cancer bowel disease. 2022 , 12,	0
38	Cancer Gene Therapy. 1-11	0
37	CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. 2022 , 3,	1
36	A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.	0
35	Antigenic cartography of well-characterized human sera reveal differences in neutralizing capacity based on infection and vaccination history. 2022 ,	0
34	Advances in immunotherapy for glioblastoma multiforme. 13,	0
33	Genetic scissorsCRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair. 2023 , 22, 254-273	0
32	Capturing the start point of the virusCell interaction with high-speed 3D single-virus tracking.	2
31	Generation and functional evaluation of novel monoclonal antibodies targeting glycosylated human stem cell factor.	0
30	Current strategies employed in the manipulation of gene expression for clinical purposes. 2022 , 20,	0

- 29 MSC based gene delivery methods and strategies improve the therapeutic efficacy of neurological diseases. **2023**, 23, 409-437 ○
- 28 In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations. **2022**, 13, 2222 1
- 27 The prospect of genetically engineering natural killer cells for cancer immunotherapy. **2022**, 11, ○
- 26 CAR-NK cells: a promising cellular immunotherapy in lymphoma. 1-11 ○
- 25 CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. 13, ○
- 24 Primary infection with Zika virus provides one-way heterologous protection against Spondweni virus infection in rhesus macaques. ○
- 23 Granulovacuolar degeneration bodies are independently induced by tau and ~~B~~synuclein pathology. **2022**, 14, ○
- 22 Genetic engineering and genome editing in plants, animals and humans: Facts and Myths. **2022**, 147141 ○
- 21 An adaptive, negative feedback circuit in a biohybrid device reprograms dynamic networks of systemic inflammation in vivo. 2, ○
- 20 HIV-1 is dependent on its immature lattice to recruit IP6 for mature capsid assembly. ○
- 19 Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry. **2023**, 28, 474 2
- 18 <https://elsevier.proofcentral.com/en-us/landing-page.html?token=baf280639f2773e07701834b1c13da>Inhibition of spermatogenesis by hypoxia is mediated by V-ATPase via the JNK/c-Jun pathway in mice. **2023**, 23, 100761 ○
- 17 A straightforward microfluidic-based approach toward optimizing transduction efficiency of HIV-1-derived lentiviral vectors in BCP-ALL cells. **2023**, 38, e00792 ○
- 16 Advances in transgene delivery for the generation of transgenic livestock. **2023**, 29-59 ○
- 15 A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. **2023**, 186, 1263-1278.e20
- 14 Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. 14, 1
- 13 The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11. **2023**, 42, 112234 ○
- 12 Molecular Basis and Genetic Modifiers of Thalassemia. **2023**, 37, 273-299 ○

- 11 Ex vivo gene therapy for lysosomal storage disorders: future perspectives. 1-12 o
- 10 Pseudotyped Viruses. **2023**, 1-27 o
- 9 Pseudotyped Viruses for Influenza. **2023**, 153-173 o
- 8 Nano-vaccines for gene delivery against HIV-1 infection. **2023**, 22, 315-326 o
- 7 A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9. **2023**, 8, o
- 6 BCL7A is silenced by hypermethylation to promote acute myeloid leukemia. **2023**, 11, o
- 5 A custom-made AAV1 variant (AAV1-T593K) enables efficient transduction of Japanese quail neurons in vitro and in vivo. **2023**, 6, o
- 4 APOBEC3 degradation is the primary function of HIV-1 Vif for virus replication in the myeloid cell line THP-1. o
- 3 Nanotechnology-enabled gene delivery for cancer and other genetic diseases. 1-18 o
- 2 Ewing sarcoma treatment: a gene therapy approach. o
- 1 Species-specific MARCO-alphavirus interactions dictate chikungunya virus viremia. **2023**, 42, 112418 o